

```




chain nodes :
  14 15 17
ring nodes :
  1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 22 23
chain bonds :
  5-9 8-17 12-20 14-15
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 18-19 18-23
  19-20 20-21 21-22 22-23
exact/norm bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 5-9 8-9 8-12 8-17 9-10 10-11 11-12
  12-20 14-15
normalized bonds :
  18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
  containing 8 : 18 :
  
```

G1:C,N

G2:CH2,CH, [*1]

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom
  11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
  21:Atom 22:Atom 23:Atom
  
```



```

chain nodes :
  14 15 17 28
ring nodes :
  1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 22 23 25 26 27
chain bonds :
  5-9 8-17 12-20 14-15 26-28
ring bonds :
  1-2 1-6 2-3 2-25 3-4 3-27 4-5 5-6 8-9 8-12 9-10 10-11 11-12
  18-19 18-23 19-20 20-21 21-22 22-23 25-26 26-27
exact/norm bonds :
  1-2 1-6 2-3 2-25 3-4 3-27 4-5 5-6 5-9 8-9 8-12 8-17 9-10 10-11
  11-12 12-20 14-15 25-26 26-27 26-28
normalized bonds :
  18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
  containing 8 : 18 :
  
```



G1:C,N

G2:CH2,CH, [*1]

G3:O,NH

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom
  11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
  21:Atom 22:Atom 23:Atom 25:Atom 26:Atom 27:Atom 28:CLASS
  
```



chain nodes :

14 15 17 30

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 22 23 25 26 27

chain bonds :

5-9 8-17 12-20 14-15 27-30

ring bonds :

1-2 1-6 2-3 2-25 3-4 3-27 4-5 5-6 8-9 8-12 9-10 10-11 11-12
18-19 18-23 19-20 20-21 21-22 22-23 25-26 26-27

exact/norm bonds :

1-2 1-6 2-3 2-25 3-4 3-27 4-5 5-6 5-9 8-9 8-12 8-17 9-10 10-11
11-12 12-20 14-15 25-26 26-27 27-30

normalized bonds :

18-19 18-23 19-20 20-21 21-22 22-23

isolated ring systems :

containing 8 : 18 :



G1:C,N

G2:CH2,CH, [*1]

G3:O,NH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 25:Atom 26:Atom 27:Atom 30:CLASS



chain nodes :

14 15 17

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 22 23

chain bonds :

5-9 8-17 12-20 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 18-19 18-23
19-20 20-21 21-22 22-23

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 8-9 8-12 8-17 9-10 10-11 11-12
12-20 14-15

normalized bonds :

18-19 18-23 19-20 20-21 21-22 22-23

isolated ring systems :


containing 1 : 8 : 18 :

G1:C,N

G2:CH2,CH, [*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom



chain nodes :

14 15 17 25 26 27 29 30 31 34 35 36 39

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 18 19 20 21 22 23

chain bonds :

5-9 8-17 12-20 14-15 25-26 26-27 29-30 29-31 34-35 35-39

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12 18-19 18-23
19-20 20-21 21-22 22-23

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 8-9 8-12 8-17 9-10 10-11 11-12
12-20 14-15 25-26 26-27 29-30 29-31 34-35 35-39

normalized bonds :

18-19 18-23 19-20 20-21 21-22 22-23

isolated ring systems :

containing 1 : 8 : 18 :

G1:C,N

G2:CH2,CH,[*1]

G3:O,N,[*2],[*3]

G4:Cy,[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 14:CLASS 15:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 25:CLASS 26:CLASS 27:CLASS 29:CLASS 30:CLASS
31:CLASS 34:CLASS 35:CLASS 36:CLASS 39:CLASS

10501317

=>.d his

(FILE 'HOME' ENTERED AT 10:37:44 ON 08 AUG 2007)

FILE 'REGISTRY' ENTERED AT 10:37:57 ON 08 AUG 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 1825 S L2 FULL

FILE 'HCAPLUS' ENTERED AT 10:43:09 ON 08 AUG 2007

L4 567 S L3

FILE 'REGISTRY' ENTERED AT 10:45:33 ON 08 AUG 2007

L5 STRUCTURE UPLOADED
L6 0 S L5
L7 0 S L5 FULL
L8 STRUCTURE UPLOADED
L9 0 S L8
L10 0 S L8 FULL
L11 STRUCTURE UPLOADED
L12 50 S L11
L13 STRUCTURE UPLOADED
L14 17 S L13
L15 309 S L13 FULL

FILE 'HCAPLUS' ENTERED AT 10:55:47 ON 08 AUG 2007

L16 27 S L15
L17 2 S L16 AND BROMIDGE, S?/AU
L18 25 S L16 NOT L17
L19 0 S L18 AND LOVELL, P?/AU
L20 0 S L18 AND GOODACRE, C?/AU

FILE 'CAOLD' ENTERED AT 10:57:37 ON 08 AUG 2007

=> s 115

L21 0 L15

=>

10501317

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAY 01 New CAS web site launched
NEWS 3 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 4 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 6 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 7 MAY 21 CA/Caplus enhanced with additional kind codes for German patents
NEWS 8 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents
NEWS 9 JUN 27 CA/Caplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10 JUN 29 STN Viewer now available
NEWS 11 JUN 29 STN Express, Version 8.2, now available
NEWS 12 JUL 02 LEMBASE coverage updated
NEWS 13 JUL 02 LMEDLINE coverage updated
NEWS 14 JUL 02 SCISEARCH enhanced with complete author names
NEWS 15 JUL 02 CHEMCATS accession numbers revised
NEWS 16 JUL 02 CA/Caplus enhanced with utility model patents from China
NEWS 17 JUL 16 Caplus enhanced with French and German abstracts
NEWS 18 JUL 18 CA/Caplus patent coverage enhanced
NEWS 19 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20 JUL 30 USGENE now available on STN
NEWS 21 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 22 AUG 06 BEILSTEIN updated with new compounds
NEWS 23 AUG 06 FSTA enhanced with new thesaurus edition

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Updated Search

10501317

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:37:44 ON 08 AUG 2007.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:37:57 ON 08 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2007 HIGHEST RN 944239-85-4

DICTIONARY FILE UPDATES: 7 AUG 2007 HIGHEST RN 944239-85-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\earer.str

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:42:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 522 TO ITERATE

100.0% PROCESSED 522 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

Updated Search

10501317

PROJECTED ITERATIONS: 9070 TO 11810
PROJECTED ANSWERS: 1316 TO 2484

L2 50 SEA SSS SAM L1

=> s 12 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:43:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10469 TO ITERATE

100.0% PROCESSED 10469 ITERATIONS 1825 ANSWERS
SEARCH TIME: 00.00.01

L3 1825 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	175.70	175.91

FILE 'HCAPLUS' ENTERED AT 10:43:09 ON 08 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 7 Aug 2007 (20070807/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 567 L3

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.40	186.31

FILE 'REGISTRY' ENTERED AT 10:45:33 ON 08 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

Updated Search

10501317

provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2007 HIGHEST RN 944239-85-4
DICTIONARY FILE UPDATES: 7 AUG 2007 HIGHEST RN 944239-85-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\azqwe.str

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 10:47:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s 15 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:47:42 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 154 TO ITERATE

100.0% PROCESSED 154 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L7 0 SEA SSS FUL L5

=>

Updated Search

10501317

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\1a212df.str

L8 STRUCTURE UPLOADED

=> d 18

L8 HAS NO ANSWERS

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 18

SAMPLE SEARCH INITIATED 10:49:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L9 0 SEA SSS SAM L8

=> s 18 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:49:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L10 0 SEA SSS FUL L8

=>

Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\werergytuy.str

L11 STRUCTURE UPLOADED

=> d 111

L11 HAS NO ANSWERS

L11 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 111

SAMPLE SEARCH INITIATED 10:50:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 522 TO ITERATE

100.0% PROCESSED 522 ITERATIONS

50 ANSWERS

Updated Search

10501317

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9070 TO 11810
PROJECTED ANSWERS: 1181 TO 2299

L12 50 SEA SSS SAM L11

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\ererererenmj.str

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l13
SAMPLE SEARCH INITIATED 10:55:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 512 TO ITERATE

100.0% PROCESSED 512 ITERATIONS 17 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8883 TO 11597
PROJECTED ANSWERS: 93 TO 587

L14 17 SEA SSS SAM L13

=> s l13 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:55:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 10285 TO ITERATE

100.0% PROCESSED 10285 ITERATIONS 309 ANSWERS
SEARCH TIME: 00.00.01

L15 309 SEA SSS FUL L13

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	522.60	708.91

FILE 'HCAPLUS' ENTERED AT 10:55:47 ON 08 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Updated Search

10501317

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 7 Aug 2007 (20070807/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l15

L16 27 L15

=> s l16 and bromidge, s?/au

79 BROMIDGE, S?/AU

L17 2 L16 AND BROMIDGE, S?/AU

=> d l17, ibib abs hitstr, 1-2

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1084921 HCAPLUS

DOCUMENT NUMBER: 143:432011

TITLE: A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT_{2C} receptor antagonists

AUTHOR(S): Goodacre, Caroline J.; Bromidge, Steven M.; Clapham, David; King, Frank D.; Lovell, Peter J.; Allen, Mike; Campbell, Lorraine P.; Holland, Vicky; Riley, Graham J.; Starr, Kathryn R.; Trail, Brenda K.; Wood, Martyn D.

CORPORATE SOURCE: Psychiatry Centre of Excellence in Drug Discovery, GlaxoSmithkline Pharmaceuticals, Essex, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(22), 4989-4993

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:432011

GI

Updated Search

10501317



AB Bisaryl cyclic ureas have been identified as high affinity 5-HT_{2C} receptor antagonists with selectivity over 5-HT_{2A} and 5-HT_{2B}. Compds. such as (I) and (II) have shown oral activity in a centrally mediated pharmacodynamic model of 5-HT_{2C} function in rodents.


IT 561277-51-8P 561277-52-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT_{2C} receptor antagonists)

RN 561277-51-8 HCAPLUS


CN 2H-Imidazol-2-one, 1-(3-fluorophenyl)-1,3-dihydro-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-52-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-(3,5-difluorophenyl)-1,3-dihydro-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317




IT 561277-37-0P, 1-(3-Fluorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-38-1P
561277-39-2P 561277-40-5P 561277-41-6P
561277-42-7P, 1-[4-Methoxy-3-(2-(piperidinyl)ethoxy)phenyl]-3-phenylimidazolidin-2-one 561277-43-8P 561277-45-0P,
1-(3,4-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-46-1P 561277-47-2P
561277-48-3P 561277-50-7P, 1-(2,3-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one
561277-53-0P 868568-29-0P 868568-37-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT_{2C} receptor antagonists)

RN 561277-37-0 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 561277-38-1 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 561277-39-2 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561277-40-5 HCAPLUS


CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 561277-41-6 HCAPLUS

CN 2-Imidazolidinone, 1-(2-chlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


10501317



RN 561277-42-7 HCAPLUS
CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 561277-43-8 HCAPLUS
CN 2-Imidazolidinone, 1-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 561277-45-0 HCAPLUS

Updated Search


10501317

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-46-1 HCAPLUS


CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-47-2 HCAPLUS


CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)


10501317




RN 561277-48-3 HCAPLUS
CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 561277-50-7 HCAPLUS
CN 2-Imidazolidinone, 1-(2,3-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 561277-53-0 HCAPLUS
CN 2,4-Imidazolidinedione, 3-(3-fluorophenyl)-1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 868568-29-0 HCAPLUS
CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[6-(2-pyridinylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 868568-37-0 HCAPLUS
CN 2-Imidazolidinone, 1-(3,5-difluorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



10501317


IT 561277-24-5 561277-25-6 868568-59-6
868568-61-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT_{2C} receptor antagonists)


RN 561277-24-5 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-(phenylmethoxy)phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 561277-25-6 HCAPLUS

CN 2-Imidazolidinone, 1-(2-chlorophenyl)-3-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 868568-59-6 HCAPLUS


CN 2-Imidazolidinone, 1-(2,3-dichlorophenyl)-3-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Updated Search

10501317




RN 868568-61-0 HCAPLUS
CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT 561277-23-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT_{2C} receptor antagonists)
RN 561277-23-4 HCAPLUS
CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Updated Search

10501317




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:551382 HCAPLUS
 DOCUMENT NUMBER: 139:117423
 TITLE: Preparation of cyclic urea derivatives with 5-HT2c receptor activity
 INVENTOR(S): Bromidge, Steven Mark; Lovell, Peter John; Goodacre, Caroline
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057220	A1	20030717	WO 2003-GB20	20030107
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003201636	A1	20030724	AU 2003-201636	20030107
EP 1465630	A1	20041013	EP 2003-700335	20030107
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005154028	A1	20050714	US 2003-501317	20030107
JP 2005524620	T	20050818	JP 2003-557578	20030107
PRIORITY APPLN. INFO.:			GB 2002-283	A 20020108
			WO 2003-GB20	W 20030107
OTHER SOURCE(S):	MARPAT 139:117423			
GI				

Updated Search



I



II

AB Title compds. I [$p = 0-5$; $m = 1-3$; $Y = N, C$; $A = O, N, CONH, NHCO$, etc.; $R_1 = \text{halo, alkyl, alkoxy, alkylthio, etc.}$; $R_2 = H, \text{halo, alkyl, alkoxy, haloalkyl, haloalkoxy}$; $R_3 = \text{amino}$; $X = CH_2, CO$] are prepared. For instance, 2-(3-fluorophenylamino)ethanol (preparation given) is reacted with $MsCl/CH_2Cl_2$ followed by 3-benzyloxy-4-methoxyphenylamine to give the corresponding substituted diamine. This intermediate is treated with phosgene to give 1-(3-benzyloxy-4-methoxyphenyl)-3-(3-fluorophenyl)imidazolidin-2-one. Substitution of this using 1-(2-chloroethyl)piperidine $\cdot HCl$ ($MeOCH_2CH_2OMe$, K_2CO_3 , reflux, 5 h) afforded II. I exhibit 5-HT_{2c} receptor activity and are useful for the treatment of CNS disorders such as depression or anxiety.

IT 561277-37-0P, 1-(3-Fluorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-38-1P, 1-(3-Fluorophenyl)-3-[4-methoxy-3-(2-(morpholinyl)ethoxy)phenyl]imidazolidin-2-one 561277-39-2P, 1-(4-Methyl-3-trifluoromethylphenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-40-5P, 1-(4-Methyl-3-trifluoromethylphenyl)-3-[4-methoxy-3-(2-(morpholinyl)ethoxy)phenyl]imidazolidin-2-one 561277-41-6P, 1-(2-Chlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-42-7P, 1-[4-Methoxy-3-(2-(piperidinyl)ethoxy)phenyl]-3-phenylimidazolidin-2-one 561277-43-8P, 1-[3-(2-Dimethylaminoethoxy)-4-methoxyphenyl]-3-(3-fluorophenyl)imidazolidin-2-one 561277-44-9P 561277-45-0P, 1-(3,4-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-46-1P, 1-(3,4-Dichlorophenyl)-3-[4-methoxy-3-(2-(morpholinyl)ethoxy)phenyl]imidazolidin-2-one 561277-47-2P, 1-(3,4-Dichlorophenyl)-3-[3-(2-dimethylaminoethoxy)-4-methoxyphenyl]imidazolidin-2-one 561277-48-3P, 1-(3,4-Dichlorophenyl)-3-[6-(2-(piperidinyl)ethoxy)pyridin-3-yl]imidazolidin-2-one 561277-49-4P, 1-[4-Bromo-3-(2-(piperidinyl)ethoxy)phenyl]-3-(3,4-dichlorophenyl)imidazolidin-2-one 561277-50-7P, 1-(2,3-Dichlorophenyl)-3-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazolidin-2-one 561277-51-8P 561277-52-9P 561277-53-0P, 3-(3-Fluorophenyl)-1-[4-methoxy-3-(2-(piperidinyl)ethoxy)phenyl]imidazol-2,4-dione
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


10501317

(Uses)

(preparation of cyclic urea derivs. with 5-HT_{2C} receptor activity)


RN 561277-37-0 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 561277-38-1 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-39-2 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




Updated Search

10501317


RN 561277-40-5 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 561277-41-6 HCAPLUS

CN 2-Imidazolidinone, 1-(2-chlorophenyl)-3-[4-methoxy-3-[2-(1-piperidiny)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-42-7 HCAPLUS

CN 2-Imidazolidinone, 1-[4-methoxy-3-[2-(1-piperidiny)ethoxy]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 561277-43-8 HCAPLUS

CN 2-Imidazolidinone, 1-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]-3-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 561277-44-9 HCAPLUS
CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-[2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 561277-45-0 HCAPLUS
CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 561277-46-1 HCAPLUS

Updated Search


10501317

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-47-2 HCAPLUS

CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[3-[2-(dimethylamino)ethoxy]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 561277-48-3 HCAPLUS


CN 2-Imidazolidinone, 1-(3,4-dichlorophenyl)-3-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A




RN 561277-49-4 HCAPLUS
CN 2-Imidazolidinone, 1-[4-bromo-3-[2-(1-piperidinyl)ethoxy]phenyl]-3-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

10501317




RN 561277-50-7 HCAPLUS
CN 2-Imidazolidinone, 1-(2,3-dichlorophenyl)-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-51-8 HCAPLUS
CN 2H-Imidazol-2-one, 1-(3-fluorophenyl)-1,3-dihydro-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 561277-52-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-(3,5-difluorophenyl)-1,3-dihydro-3-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 561277-53-0 HCAPLUS


CN 2,4-Imidazolidinedione, 3-(3-fluorophenyl)-1-[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




Updated Search

10501317

IT 561277-13-2P, 1-(3-Benzyloxy-4-methoxyphenyl)-3-(3-fluorophenyl)imidazolidine-2,4-dione 561277-23-4P, 1-(3-Benzyloxy-4-methoxyphenyl)-3-(3-fluorophenyl)imidazolidin-2-one 561277-24-5P, 1-(3-Benzyloxy-4-methoxyphenyl)-3-(4-methyl-3-trifluoromethylphenyl)imidazolidin-2-one 561277-25-6P, 1-(3-Benzyloxy-4-methoxyphenyl)-3-(2-chlorophenyl)imidazolidin-2-one 561277-30-3P, 1-[3-(2-Benzyloxyethoxy)-4-methoxyphenyl]-3-(3-fluorophenyl)imidazolidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic urea derivs. with 5-HT_{2C} receptor activity)
RN 561277-13-2 HCAPLUS
CN 2,4-Imidazolidinedione, 3-(3-fluorophenyl)-1-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 561277-23-4 HCAPLUS
CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 561277-24-5 HCAPLUS
CN 2-Imidazolidinone, 1-[4-methoxy-3-(phenylmethoxy)phenyl]-3-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 561277-25-6 HCAPLUS

CN 2-Imidazolidinone, 1-(2-chlorophenyl)-3-[4-methoxy-3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 561277-30-3 HCAPLUS

CN 2-Imidazolidinone, 1-(3-fluorophenyl)-3-[4-methoxy-3-(2-(phenylmethoxy)ethoxy)phenyl]- (9CI) (CA INDEX NAME)

Updated Search

10501317



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:37:44 ON 08 AUG 2007)

FILE 'REGISTRY' ENTERED AT 10:37:57 ON 08 AUG 2007

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 1825 S L2 FULL

FILE 'HCAPLUS' ENTERED AT 10:43:09 ON 08 AUG 2007

L4 567 S L3

FILE 'REGISTRY' ENTERED AT 10:45:33 ON 08 AUG 2007

L5 STRUCTURE UPLOADED

L6 0 S L5

L7 0 S L5 FULL

L8 STRUCTURE UPLOADED

L9 0 S L8

L10 0 S L8 FULL

L11 STRUCTURE UPLOADED

L12 50 S L11

L13 STRUCTURE UPLOADED

L14 17 S L13

L15 309 S L13 FULL

FILE 'HCAPLUS' ENTERED AT 10:55:47 ON 08 AUG 2007

L16 27 S L15

L17 2 S L16 AND BROMIDGE, S?/AU

=> s 116 not 117

L18 25 L16 NOT L17

=> s 118 and lovell, p?/au

176 LOVELL, P?/AU

L19 0 L18 AND LOVELL, P?/AU

=> s 118 and goodacre, c?/au

20 GOODACRE, C?/AU

Updated Search

10501317

L20 0 L18 AND GOODACRE, C?/AU

=> d l18, ibib abs hitstr, 1-25

L18 ANSWER 1 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:117937 HCAPLUS

DOCUMENT NUMBER: 146:206302

TITLE: Preparation of hydantoin derivatives and their use as MCHR-1 antagonists

INVENTOR(S): Balavoine, Fabrice; Nicolaie, Eric; Sartori, Eric

PATENT ASSIGNEE(S): Cerep, Fr.

SOURCE: PCT Int. Appl., 92pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007012661	A1	20070201	WO 2006-EP64747	20060727
WO 2007012661	A8	20070329		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2889189	A1	20070202	FR 2005-8064	20050728
PRIORITY APPLN. INFO.:			FR 2005-8064	A 20050728

OTHER SOURCE(S): MARPAT 146:206302

GI



I



II

AB Title compds. I [Ar1 = (un)substituted aryl, heteroaryl, cycloalkyl, heterocyclyl; L1 = bond, alkylene, alkyleneoxy, alkoxyalkylene, alkylidene, alkylidenoxy; R1, R2 = H, alkyl; R1 or R2 can form with Ar2 or L and with the C and N atoms of the hydantoin ring to which they are attached a 5-7 membered heterocycle; when R1 or R2 binds to Ar2 or L, then R1 or R2 = alkylene; L = bond, alkylene, alkyleneoxy, alkylidene; Ar2 = (un)substituted aryl, heteroaryl, heterocyclyl; L2 = alkylene, alkyleneoxy, alkylidene, etc.; Q = NH2 and derivs.] were prepared as melanin-concentrating hormone receptor type 1 (MCHR-1) antagonists for treating and prevention of diseases associated with MCHR receptors such as obesity, anorexia, weight loss, depression and/or anxiety. Thus, O-alkylation of 2-methoxy-4-nitrophenol potassium salt with 1-(2-chloroethyl)pyrrolidine.HCl, reduction of the nitro intermediate, reaction of the amine with Et glyoxylate, and cyclization with 4-phenoxyphenyl isocyanate gave II. I displayed a good affinity for the MCHR-1 receptors (IC50 < 200 nM for II). The antagonistic activity of hydantoins I was demonstrated in a fluorescence assay following the intracellular calcium release induced by MCH (no data).

IT 923030-45-9P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-48-2P, 3-(Biphenyl-4-yl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-49-3P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(3-phenoxyphenyl)imidazolidine-2,4-dione 923030-50-6P, 3-(4-Butoxyphenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-51-7P, 3-(4-Benzylphenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-60-8P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-phenylimidazolidine-2,4-dione 923030-61-9P, 3-(4-Chlorophenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-62-0P, 3-(4-Methoxyphenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-63-1P, 3-(4-Bromophenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-64-2P, 3-(4-Fluorophenyl)-1-[3-methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-65-3P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-methylphenyl)imidazolidine-2,4-dione 923030-66-4P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-trifluoromethoxyphenyl)imidazolidine-2,4-dione 923030-67-5P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-(4-trifluoromethylphenyl)imidazolidine-2,4-dione 923030-68-6P, 3-(4-Cyanophenyl)-1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]imidazolidine-2,4-dione 923030-69-7P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-3-[4-(4-chlorophenoxy)phenyl]imidazolidine-2,4-dione 923030-70-0P, 1-[3-Methoxy-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-5-methyl-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-76-6P, 1-[4-[2-(Cyclopentylamino)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-80-2P, 1-[4-(2-Dimethylaminoethoxy)-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-81-3P, 1-[4-(2-Diethylaminoethoxy)-3-methoxyphenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-82-4P, 1-[3-Methoxy-4-[2-(morpholin-4-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione 923030-83-5P, 1-[4-[2-(4-Acetylpiperazin-1-yl)ethoxy]-3-methoxyphenyl]-3-(4-

10501317

phenoxyphenyl)imidazolidine-2,4-dione 923030-84-6P,

1-[3-Methoxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-3-(4-phenoxyphenyl)imidazolidine-2,4-dione


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of hydantoins as MCHR-1 antagonists)


RN 923030-45-9 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 923030-48-2 HCAPLUS

CN 2,4-Imidazolidinedione, 3-[1,1'-biphenyl]-4-yl-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A





RN 923030-49-3 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(3-phenoxyphenyl)- (CA INDEX NAME)



Updated Search




RN 923030-50-6 HCAPLUS
CN 2,4-Imidazolidinedione, 3-(4-butoxyphenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 923030-51-7 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-[4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 923030-60-8 HCAPLUS
 CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-phenyl- (CA INDEX NAME)




RN 923030-61-9 HCAPLUS
 CN 2,4-Imidazolidinedione, 3-(4-chlorophenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 923030-62-0 HCAPLUS
CN 2,4-Imidazolidinedione, 3-(4-methoxyphenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 923030-63-1 HCAPLUS
CN 2,4-Imidazolidinedione, 3-(4-bromophenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 923030-64-2 HCAPLUS
CN 2,4-Imidazolidinedione, 3-(4-fluorophenyl)-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 923030-65-3 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-(4-methylphenyl)- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 923030-66-4 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A




RN 923030-67-5 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-3-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 923030-68-6 HCAPLUS
CN Benzonitrile, 4-[3-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2,5-dioxo-1-imidazolidinyl]- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A



RN 923030-69-7 HCAPLUS
CN 2,4-Imidazolidinedione, 3-[4-(4-chlorophenoxy)phenyl]-1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)


Updated Search




RN 923030-70-0 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5-methyl-3-(4-phenoxyphenyl)- (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 923030-76-6 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[4-[2-(cyclopentylamino)ethoxy]-3-methoxyphenyl]-
3-(4-phenoxyphenyl)- (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 923030-80-2 HCAPLUS
CN 2,4-Imidazolidinedione, 1-[4-[2-(dimethylamino)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)

Updated Search


10501317



Me₂N-CH₂-CH₂-O

RN 923030-81-3 HCAPLUS


CN 2,4-Imidazolidinedione, 1-[4-[2-(diethylamino)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



Et₂N-CH₂-CH₂-O

RN 923030-82-4 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)




RN 923030-83-5 HCAPLUS

Updated Search


10501317

CN 2,4-Imidazolidinedione, 1-[4-[2-(4-acetyl-1-piperazinyl)ethoxy]-3-methoxyphenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 923030-84-6 HCAPLUS

CN 2,4-Imidazolidinedione, 1-[3-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:542661 HCAPLUS

DOCUMENT NUMBER: 145:46082

TITLE: Preparation of substituted heterocycles for treating HGF mediated diseases

INVENTOR(S): Kim, Tae-Seong; Bellon, Steven; Booker, Shon; D'Angelo, Noel; Dominguez, Celia; Fellows, Ingrid; Lee, Matthew; Liu, Longbin; Rainbeau, Elizabeth; Siegmund, Aaron C.; Tasker, Andrew; Xi, Ning; Cheng, Yuan

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 228 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060318	A2	20060608	WO 2005-US42935	20051129
WO 2006060318	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,



Updated Search

10501317

SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

AU 2005312048	A1	20060608	AU 2005-312048	20051129
US 2006252777	A1	20061109	US 2005-289659	20051129
PRIORITY APPLN. INFO.:			US 2004-632271P	P 20041130
			WO 2005-US42935	W 20051129

OTHER SOURCE(S): MARPAT 145:46082
GI



AB The title compds. R1XWAYR [I; R = (un)substituted aryl, heterocyclyl, cycloalkyl, etc.; R1 = II (wherein ring T = Ph, 5-6 membered heteroaryl; Z = N or CH; R10 = alkoxy, haloalkoxy, arylalkoxy, etc.); W = (un)substituted aryl, 5-6 membered heteroaryl; A = (un)substituted 5-7 membered N-containing heterocyclyl; X = O, S, NR2, CR3R4; Y = a bond, CO, CONH, etc.; R2 = H, alkyl, haloalkyl, etc.; R3, R4 = H, alkyl, aryl, etc.] which are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from 2-benzyl-3H-pyrimidin-4-one, was given. Compds. I showed inhibition of c-Met kinase at doses less than 2 μ M. The invention encompasses novel compds. I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compds. as well as to intermediates useful in such processes.

Updated Search

10501317


IT 890020-63-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heterocycles for treating HGF mediated diseases)

RN 890020-63-0 HCAPLUS

CN 2,4-Imidazolidinedione, 3-[3-fluoro-4-[[6-methoxy-7-(phenylmethoxy)-4-quinolinyloxy]phenyl]-1-phenyl- (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:235075 HCAPLUS

DOCUMENT NUMBER: 144:312085

TITLE: Preparation of imidazolidine derivatives as antiandrogens

INVENTOR(S): Tachibana, Kazutaka; Sato, Haruhiko; Ohta, Masateru; Nakamura, Mitsuaki; Shiraishi, Takuya; Yoshino, Hitoshi; Emura, Takashi; Honma, Akie; Onuma, Etsuro; Kawata, Hiromitsu; Taniguchi, Kenji

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 206 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006028226	A1	20060316	WO 2005-JP16664	20050909
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

Updated Search

10501317

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM



AU 2005280908	A1	20060316	AU 2005-280908	20050909
CA 2579886	A1	20060316	CA 2005-2579886	20050909
EP 1790640	A1	20070530	EP 2005-782020	20050909

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:

JP 2004-262888	A	20040909
WO 2005-JP16664	W	20050909

OTHER SOURCE(S): MARPAT 144:312085
GI



AB The title compds. I [Q = Q1, etc.; A = H, halo, ORa, etc.; E = alkyl; m = integer from 0 to 3; R2, R3 = alkyl; X1, X2 = O, S; Y = (un)substituted arylene, divalent (un)substituted 5- or 6-membered monocyclic heterocyclic group or divalent 8 to 10 membered (un)substituted fused-ring heterocyclic group; Z = CO, CO2, SO2, etc.; R1 = H, OH, (un)substituted alkyl, etc.; Ra = H, (un)substituted alkyl, (un)substituted alkylcarbonyl, etc.] are prepared. Thus, 4-[3-(1-ethoxycarbonylpiperidin-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile was prepared in a multistep process. The androgen antagonist activities of compds. of this invention were demonstrated.


IT 879613-36-2P 879613-49-7P 879613-51-1P
879613-55-5P 879613-57-7P 879613-61-3P
879613-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolidine derivs. as antiandrogens)

RN 879613-36-2 HCAPLUS

CN 1-Piperazineacetamide, N-[2-chloro-4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]- (9CI) (CA INDEX NAME)




Updated Search

10501317


RN 879613-49-7 HCAPLUS

CN Carbamic acid, [2-chloro-5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 879613-51-1 HCAPLUS


CN Carbamic acid, [2-chloro-5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]-, 2-(4-methyl-1-piperazinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 879613-55-5 HCAPLUS


CN Carbamic acid, [2-chloro-5-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)

10501317



RN 879613-57-7 HCAPLUS

CN Carbamic acid, [2-chloro-5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]-, 3-(dimethylamino)propyl ester (9CI) (CA INDEX NAME)




RN 879613-61-3 HCAPLUS

CN Carbamic acid, [2-chloro-5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]-, 2-[[[1,1-dimethylethoxy)carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 879613-65-7 HCAPLUS

CN Carbamic acid, [2-chloro-5-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]-, 2-aminoethyl ester (9CI)
(CA INDEX NAME)



IT 879614-84-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of imidazolidine derivs. as antiandrogens)

RN 879614-84-3 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[2-chloro-4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Updated Search

10501317



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1123789 HCAPLUS

DOCUMENT NUMBER: 143:427366

TITLE: Compositions and methods for treatment of inflammatory conditions using steroid sparing agents

INVENTOR(S): Lieberburg, Ivan

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 782 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097162	A2	20051020	WO 2005-US11307	20050401
WO 2005097162	A3	20060406		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005231467	A1	20051020	AU 2005-231467	20050401
CA 2561164	A1	20051020	CA 2005-2561164	20050401
US 2006004019	A1	20060105	US 2005-95822	20050401
EP 1763361	A2	20070321	EP 2005-763852	20050401
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2004-558121P	P 20040401
			WO 2005-US11307	W 20050401

OTHER SOURCE(S): MARPAT 143:427366

AB This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft vs. host disease (GVHD), host vs. graft disease, and various spondyloarthropathies, comprising administering a steroid sparing Ig that modulates $\alpha 4 \beta 1$ and $\alpha 4 \beta 7$ integrins, or an amino acid-based small (heterocyclic) mol. to a patient in need thereof. The

10501317

invention also relates generally to combination therapies for the treatment of these conditions, including an immunosuppressant, an anti-TNF compound, and a 5-ASA compound. For example, a steroid sparing agent was prepared by converting L-tyrosine tert-Bu ester to L-4-(N,N-dimethylcarbamoyloxy)-phenylalanine tert-Bu ester and coupling it to 4,6-dichloro-5-piperidin-1-yl-pyrimidine to give N-(5-piperidin-yl)pyrimidin-4-yl-L-4-(N,N-dimethylcarbamoyloxy)phenylalanine. Also, Natalizumab, a humanized monoclonal IgG4 antibody to $\alpha 4$ integrin, was evaluated in subjects with Chron's disease. Monthly administration of Natalizumab for 6 mo was well tolerated and enabled subjects to be successfully withdrawn from steroids.


IT 220303-56-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of steroid sparing agents for treatment of inflammatory conditions)

RN 220303-56-0 HCAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 5 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1016895 HCAPLUS

DOCUMENT NUMBER: 143:415586

TITLE: G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation

AUTHOR(S): Rolland, Catherine; Gozalbes, Rafael; Nicolaie, Eric; Paugam, Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos; Revah, Frederic

CORPORATE SOURCE: Cerep, Rueil-Malmaison, 92500, Fr.

SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6563-6574

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A QSAR model accounting for "average" G-protein-coupled receptor (GPCR) binding was built from a large set of exptl. standardized binding data (1939 compds. systematically tested over 40 different GPCRs) and applied to the design of a library of "GPCR-predicted" compds. Three hundred and sixty of these compds. were randomly selected and tested in 21 GPCR binding assays. Positives were defined by their ability to inhibit by more than 70% the binding of reference compds. at 10 μ M. A 5.5-fold

Updated Search

10501317


enrichment in positives was observed when comparing the "GPCR-predicted" compds. with 600 randomly selected compds. predicted as "non-GPCR" from a general collection. The model was efficient in predicting strongest binders, since enrichment was greater for higher cutoffs. Significant enrichment was also observed for peptidic GPCRs and receptors not included to develop the QSAR model, suggesting the usefulness of the model to design ligands binding with newly identified GPCRs, including orphan ones.

IT 654010-68-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(QSAR design, synthesis, and exptl. validation of G-protein-coupled receptor affinity prediction based on use of a profiling dataset)

RN 654010-68-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:14169 HCAPLUS

DOCUMENT NUMBER: 142:114470

TITLE: Preparation of sulfonylated peptide derivatives for treating rheumatoid arthritis

INVENTOR(S): Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 736 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000246	A2	20050106	WO 2004-US20280	20040625
WO 2005000246	A3	20051124		

Updated Search

10501317

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004251754	A2	20050106	AU 2004-251754	20040625
AU 2004251754	A1	20050106		
CA 2529873	A1	20050106	CA 2004-2529873	20040625
US 2005065192	A1	20050324	US 2004-875282	20040625
US 2005074451	A1	20050407	US 2004-875469	20040625
EP 1635822	A2	20060322	EP 2004-777033	20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-482211P P 20030625
 WO 2004-US20280 W 20040625


OTHER SOURCE(S): MARPAT 142:114470

AB The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to $\alpha 4$ integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is -(CH2)1-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'', Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is -C(X)NR7-, where R7 is H or alkyl and X is O or S] are claimed for use in combination therapy. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to $\alpha 4\beta 1$ (IC50 $\leq 15 \mu M$).

IT 220303-56-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis)

RN 220303-56-0 HCAPLUS
 CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 7 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:14167 HCAPLUS

DOCUMENT NUMBER: 142:114469

TITLE: Preparation of sulfonated peptide derivatives for treating rheumatoid arthritis

INVENTOR(S): Yednock, Theodore A.; Freedman, Stephen B.; Lieberburg, Ivan; Pleiss, Michael A.; Konradi, Andrei W.; Shopp, George; Messersmith, Elizabeth

PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 647 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000244	A2	20050106	WO 2004-US20240	20040625
WO 2005000244	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004251750	A2	20050106	AU 2004-251750	20040625
AU 2004251750	A1	20050106		
CA 2528723	A1	20050106	CA 2004-2528723	20040625
US 2005065192	A1	20050324	US 2004-875282	20040625
US 2005074451	A1	20050407	US 2004-875469	20040625
EP 1635871	A2	20060322	EP 2004-777008	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			US 2003-482211P	P 20030625
			WO 2004-US20240	W 20040625

AB The invention relates to methods and compns. for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to $\alpha 4$ integrin or an immunol. active antigen binding fragment in therapeutically effective amts. Compds. include those described by formula R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl,

10501317

aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R2 can combine with R1 or R3 to form an (un)substituted heterocyclic group; R5 is $-(CH_2)_1-4-Ar-R_5'$, where R5' is $-O-Z-NR_8R_8'$ or $-O-Z-R_8''$, Ar is (un)substituted aryl or heteroaryl, Z is CO or SO2, R8, R8' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or NR8R8' is (un)substituted heterocyclyl, and R8'' is (un)substituted heterocyclyl; Q is $-C(X)NR_7-$, where R7 is H or alkyl and X is O or S]. Thus, N-tosyl-L-prolyl-4-(dimethylcarbamoyloxy)-L-phenylalanine Et ester was prepared by acylation of Ts-Pro-Tyr-OEt with dimethylcarbamoyl chloride. Compds. of the invention have binding affinity to $\alpha_4\beta_1$ (IC50 $\leq 15 \mu M$).

IT 220303-56-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonylated peptide derivs. for treating rheumatoid arthritis).

RN 220303-56-0 HCAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 8 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:767279 HCAPLUS

DOCUMENT NUMBER: 141:405643

TITLE: 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists

AUTHOR(S): Receveur, Jean-Marie; Bjurling, Emelie; Ulven, Trond; Little, Paul Brian; Norregaard, Pia K.; Hoegberg, Thomas

CORPORATE SOURCE: 7TM Pharma A/S, Horsholm, DK-2970, Den.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5075-5080

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 141:405643

AB Synthesis, in vitro biol. evaluation and structure-activity relationships of 4-acylamino-and 4-ureidobenzamides as novel hMCH1R-antagonists are disclosed. The nature of the amine side chains could be varied considerably in contrast to the central benzamide scaffold and aromatic

Updated Search

10501317

substituents.
IT 617246-13-6
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists)
RN 617246-13-6 HCAPLUS
CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[2-oxo-3-(4-phenoxyphenyl)-1-imidazolidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:648332 HCAPLUS
DOCUMENT NUMBER: 141:191071
TITLE: Preparation of sulfonyl dipeptides for treatment of demyelinating diseases and paralysis
INVENTOR(S): Karlik, Steve J.; Pleiss, Michael A.; Konradi, Andrei W.; Grant, Francine S.; Semko, Christopher M.; Dressen, Daren; Messersmith, Elizabeth; Freedman, Stephen; Yednock, Ted
PATENT ASSIGNEE(S): Elan Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 495 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004066932	A2	20040812	WO 2004-US2039	20040126
WO 2004066932	A3	20060601		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

Updated Search

10501317

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM,
 GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW,
 MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2004207536	A1	20040812	AU 2004-207536	20040126
CA 2514125	A1	20040812	CA 2004-2514125	20040126
US 2005069541	A1	20050331	US 2004-763424	20040126
US 2005215565	A1	20050929	US 2004-763539	20040126
EP 1592387	A2	20051109	EP 2004-705270	20040126

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1942161	A	20070404	CN 2004-80008089	20040126
JP 2007521249	T	20070802	JP 2006-503001	20040126
MX 2005PA07843	A	20051018	MX 2005-PA7843	20050722
NO 2005003920	A	20051024	NO 2005-3920	20050823
IN 2005CN01994	A	20070302	IN 2005-CN1994	20050823

PRIORITY APPLN. INFO.:	US 2003-442171P	P	20030124
	US 2003-500316P	P	20030905
	WO 2004-US2039	W	20040126

AB The application provides for methods and compns. for inhibiting demyelination, promoting remyelination and/or treating paralysis. Preferably, the compns. include Igs (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small mols., which when administered in an effective amount inhibit demyelination and/or promote remyelination. The compns. can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination. Compds. of the invention include sulfonyl dipeptides R1SO2NR2CHR3-Q-CHR5CO2H [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; R1 and R2 or R2 and R3 can form an (un)substituted heterocyclic group; R5 is -(CH2)0-4-Ar-R5', where R5' is -O-Z-NR8R8' or -O-Z-R8'' [R8, R8'' are H, (un)substituted alkyl, cycloalkyl or heterocyclyl or form a heterocycle, R8'' is (un)substituted heterocyclyl, Z is CO or SO2 and Ar is (un)substituted aryl or heteroaryl]; Q is C(X)NR7, where R7 is H or alkyl and X is O or S] or their pharmaceutically-acceptable salts. The examples describe synthetic data and specific compds. of the invention (approx. 300) which were prepared. Thus, claimed compound N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine iso-Pr ester was prepared by a peptide coupling/sulfonylation/acylation scheme and assayed for biol. activity, e.g., reversal of prolonged chronic exptl. autoimmune encephalomyelitis.

IT 220303-56-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonyl dipeptides for treatment of demyelinating diseases and paralysis)


RN 220303-56-0 HCAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10501317



L18 ANSWER 10 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:648331 HCAPLUS

DOCUMENT NUMBER: 141:191070

TITLE: Preparation of sulfonyl dipeptides for treatment of demyelinating diseases and paralysis

INVENTOR(S): Karlik, Steve J.; Pleiss, Michael A.; Konradi, Andrei W.; Grant, Francine S.; Semko, Christopher M.; Dressen, Daren; Messersmith, Elizabeth; Freedman, Stephen; Yednock, Ted

PATENT ASSIGNEE(S): Elan Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 573 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004066931	A2	20040812	WO 2004-US2028	20040126
WO 2004066931	A3	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004207535	A1	20040812	AU 2004-207535	20040126
CA 2514117	A1	20040812	CA 2004-2514117	20040126
US 2005069541	A1	20050331	US 2004-763424	20040126
US 2005215565	A1	20050929	US 2004-763539	20040126
EP 1592386	A2	20051109	EP 2004-705266	20040126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006516624	T	20060706	JP 2006-502997	20040126
MX 2005PA07823	A	20051018	MX 2005-PA7823	20050722
PRIORITY APPLN. INFO.:			US 2003-442171P	P 20030124
			US 2003-500316P	P 20030905
			WO 2004-US2028	W 20040126

OTHER SOURCE(S): MARPAT 141:191070

AB The application provides for methods and compns. for inhibiting demyelination, promoting remyelination and/or treating paralysis.

Updated Search

Preferably, the compns. include Igs (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small mols., which when administered in an effective amount inhibit demyelination and/or promote remyelination. The compns. can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination. The claims describe sulfonyl dipeptides $R1SO_2NR_2CHR_3-Q-CHR_5CO_2H$ [R1 is (un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 is H, (un)substituted cycloalkenyl or any group given for R1; R3 is H or any group given for R1; or R1 and R2 or R2 and R3 can form an (un)substituted heterocyclic group; R5 is $-(CH_2)_0-4-Ar-R_5'$, where R5' is $-O-Z-NR_8R_8'$ or $-O-Z-R_8''$ [R8, R8'' are H, R3 is (un)substituted alkyl, cycloalkyl or heterocyclyl or form a heterocycle, R8'' is (un)substituted heterocyclyl, Z is CO or SO₂ and Ar is (un)substituted aryl or heteroaryl]; Q is C(X)NR₇, where R₇ is H or alkyl and X is O or S] or their pharmaceutically-acceptable salts for treating demyelinating diseases. The examples describe synthetic data and specific compds. of the invention (approx. 300) which were prepared. Thus, claimed compound N-[N-(3-pyridinesulfonyl)-L-3,3-dimethyl-4-thiaprolyl]-O-[1-methylpiperazin-4-ylcarbonyl]-L-tyrosine iso-Pr ester was prepared by a peptide coupling/sulfonylation/acylation scheme and assayed for biol. activity, e.g., reversal of prolonged chronic exptl. autoimmune encephalomyelitis.

IT 220303-56-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfonyl dipeptides for treatment of demyelinating diseases and paralysis)

RN 220303-56-0 HCAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 11 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:430626 HCAPLUS

DOCUMENT NUMBER: 141:7113

TITLE: Preparation of novel heterocyclic compounds having antibacterial activity

INVENTOR(S): Selvakumar, Natesan; Das, Jagattaran; Trehan, Sanjay; Iqbal, Javed; Kumar, Magadi Sitaram; Rajagopalan, Ramanujam; Rao, Mamidi Naga Venkata Srinivasa



PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories Inc.

10501317

SOURCE: U.S. Pat. Appl. Publ., 100 pp., Cont.-in-part of U.S. Pat. Appl. 2003 65,175.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102494	A1	20040527	US 2003-613414	20030703
US 7160912	B2	20070109		
IN 2000MA01124	A	20050304	IN 2000-MA1124	20001226
US 2003065175	A1	20030403	US 2001-32392	20011221
US 7030148	B2	20060418		
ZA 2003004945	A	20040927	ZA 2003-4945	20030625
US 2004059120	A1	20040325	US 2003-632950	20030801
US 7183301	B2	20070227		
US 2006293315	A1	20061228	US 2006-511756	20060829
US 2007004712	A1	20070104	US 2006-511799	20060829
PRIORITY APPLN. INFO.:			IN 2000-MA1124	A 20001226
			IN 2001-MA15	A 20010104
			US 2001-32392	A2 20011221
			US 2003-613414	A1 20030703

OTHER SOURCE(S): MARPAT 141:7113
GI



AB The title compds. [I; R1 = NHR4 (wherein R4 = thioacyl, C(S)cycloalkoxy, C(S)aryloxy, etc.); R2, R3 = H, halo, alkyl, etc.; Y1 = O, S; Y2, Y3 = H, halo, CN, etc.; Z = O, S, CH, CH2, (un)substituted NH], useful for inhibiting the growth of bacteria in a subject having a bacterial infection (MIC values given for some of the compds. I), were prepared E.g., a multi-step synthesis of II was given. The pharmaceutical composition comprising the compound I is claimed.
IT 439902-74-6P 439902-75-7P 439902-86-0P

Updated Search

10501317

439902-87-1P 439903-25-0P 439903-26-1P

439903-36-3P 439903-76-1P 439903-77-2P

439903-78-3P 439903-79-4P 439903-80-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 4-(4-oxoimidazol-1-yl)phenyl substituted oxazolidinones having antibacterial activity)

RN 439902-74-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439902-75-7 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439902-86-0 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 439902-87-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-25-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10501317

RN 439903-26-1 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439903-36-3 HCAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439903-76-1 HCAPLUS

CN Carbamothioic acid, [[[(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 439903-77-2 HCAPLUS

CN Carbamothioic acid, [(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl-, O-ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 439903-78-3 HCAPLUS

CN Carbamothioic acid, [(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl-, O-methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 439903-79-4 HCAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 439903-80-7 HCAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



L18 ANSWER 12 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:101141 HCAPLUS
DOCUMENT NUMBER: 140:163866
TITLE: Preparation of 1,3-dihydro-1,3-diphenyl-2H-imidazol-2-ones and related compounds as MCH receptor modulators for the treatment of obesity
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Rosse, Gerard; Walser, Armin
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.		KIND	DATE	APPLICATION NO.		DATE	
WO 2004011438		A1	20040205	WO 2003-EP7891		20030718	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW						
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR						

Updated Search


10501317

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
DE 10233817	A1	20040212	DE 2002-10233817 20020725
WO 2004012648	A2	20040212	WO 2003-EP7639 20030715
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU 2003257465	A1	20040223	AU 2003-257465 20030715
CA 2493924	A1	20040205	CA 2003-2493924 20030718
AU 2003251001	A1	20040216	AU 2003-251001 20030718
BR 2003012916	A	20050614	BR 2003-12916 20030718
EP 1551810	A1	20050713	EP 2003-771060 20030718
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
JP 2006501202	T	20060112	JP 2004-523753 20030718
US 2004132752	A1	20040708	US 2003-626314 20030724
US 7141561	B2	20061128	
MX 2005PA01048	A	20050408	MX 2005-PA1048 20050125
PRIORITY APPLN. INFO.:			DE 2002-10233817 A 20020725
			US 2002-428877P P 20021125
			WO 2003-EP7639 W 20030715
			WO 2003-EP7891 W 20030718


OTHER SOURCE(S) : MARPAT 140:163866
GI



I



II



III

10501317


AB Title compds. I [R = alkyl, alkylaryl, cycloalkyl, etc.; A = (C(R42)(R43))m; m = 0-5; R42, R43 = H, alkyl, aryl; B = a bond or a link, i.e., S, SO, SO2, etc.; W = (CH2)n, CH=CH, CH=N, etc.; n = 2-5; R9, R10 = H, alkyl, alkoxyalkyl, etc.; R1, R2, R3, R4 = H, halo, OH, etc.; R5, R6, R7, R8 = H, halo, OH, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, TFA catalyzed cyclization of di-Me acetal II, e.g., prepared from 4-phenoxyaniline in 2-steps, afforded diarylcyclic urea III. In milk consumption studies with female NMRI mice, cyclic urea III exhibited very good anorectic effects, i.e., 58% decrease in milk consumption vs control. Compds. I are claimed useful as antiobesity and antidiabetic agents.

IT 654022-95-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of diarylcyclic ureas as MCH receptor modulators for the treatment of obesity)

RN 654022-95-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



Me₂N-CH₂-CH₂-O


IT 654010-72-7P 654018-61-8P 654018-77-6P
654019-23-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of diarylcyclic ureas as MCH receptor modulators for the treatment of obesity)

RN 654010-72-7 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[[2-(dimethylamino)ethyl]amino]-3-nitrophenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317



RN 654018-61-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[(2-hydroxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 654018-77-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[methyl(2-methylamino)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654019-23-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(methylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



IT 654010-68-1P 654010-79-4P 654010-85-2P
654010-92-1P 654010-99-8P 654011-07-1P
654011-15-1P 654011-29-7P 654011-41-3P
654011-47-9P 654011-54-8P 654011-60-6P
654011-65-1P 654011-71-9P 654011-76-4P
654011-82-2P 654011-88-8P 654011-93-5P

Updated Search

10501317

654011-99-1P 654012-05-2P 654012-10-9P
654012-16-5P 654012-21-2P 654012-27-8P
654012-33-6P 654012-37-0P 654012-43-8P
654012-48-3P 654012-58-5P 654012-63-2P
654012-69-8P 654012-75-6P 654012-80-3P
654012-86-9P 654012-92-7P 654012-97-2P
654013-02-2P 654013-06-6P 654013-10-2P
654013-15-7P 654013-18-0P 654013-21-5P
654013-26-0P 654013-30-6P 654013-35-1P
654013-41-9P 654013-47-5P 654013-51-1P
654013-57-7P 654013-60-2P 654013-63-5P
654013-67-9P 654013-72-6P 654013-76-0P
654013-80-6P 654013-84-0P 654013-87-3P
654013-91-9P 654013-94-2P 654013-97-5P
654014-00-3P 654014-02-5P 654014-05-8P
654014-09-2P 654014-11-6P 654014-13-8P
654014-15-0P 654014-19-4P 654014-24-1P
654014-29-6P 654014-34-3P 654014-38-7P
654014-43-4P 654014-49-0P 654014-53-6P
654014-59-2P 654014-64-9P 654014-68-3P
654014-73-0P 654014-78-5P 654014-82-1P
654014-88-7P 654014-93-4P 654014-97-8P
654015-02-8P 654015-08-4P 654015-13-1P
654015-19-7P 654015-24-4P 654015-32-4P
654015-37-9P 654015-42-6P 654015-47-1P
654015-51-7P 654015-57-3P 654015-62-0P
654015-66-4P 654015-71-1P 654015-76-6P
654015-81-3P 654015-86-8P 654015-91-5P
654015-96-0P 654016-02-1P 654016-07-6P
654016-10-1P 654016-15-6P 654016-21-4P
654016-25-8P 654016-29-2P 654016-34-9P
654016-39-4P 654016-45-2P 654016-49-6P
654016-53-2P 654016-58-7P 654016-63-4P
654016-68-9P 654016-73-6P 654016-79-2P
654016-82-7P 654016-86-1P 654016-90-7P
654016-94-1P 654017-02-4P 654017-07-9P
654017-11-5P 654017-15-9P 654017-20-6P
654017-25-1P 654017-30-8P 654017-35-3P
654017-40-0P 654017-45-5P 654017-50-2P
654017-55-7P 654017-60-4P 654017-64-8P
654017-68-2P 654017-73-9P 654017-78-4P
654017-83-1P 654017-87-5P 654017-92-2P
654017-97-7P 654018-02-7P 654018-07-2P
654018-12-9P 654018-17-4P 654018-21-0P
654018-26-5P 654018-31-2P 654018-36-7P
654018-41-4P 654018-46-9P 654018-51-6P
654018-56-1P 654018-67-4P 654018-72-1P
654018-83-4P 654018-90-3P 654018-96-9P
654019-01-9P 654019-07-5P 654019-28-0P
654019-35-9P 654019-41-7P 654019-47-3P
654019-52-0P 654019-57-5P 654019-63-3P
654019-69-9P 654019-73-5P 654019-79-1P
654019-84-8P 654019-89-3P 654019-94-0P
654019-99-5P 654020-05-0P 654020-10-7P
654020-15-2P 654020-20-9P 654020-25-4P
654020-29-8P 654020-35-6P 654020-41-4P
654020-46-9P 654020-51-6P 654020-56-1P
654020-60-7P 654020-66-3P 654020-71-0P
654020-75-4P 654020-80-1P 654020-86-7P

Updated Search

10501317

654020-92-5P 654020-99-2P 654021-04-2P
654021-10-0P 654021-16-6P 654021-22-4P
654021-27-9P 654021-32-6P 654021-37-1P
654021-48-4P 654021-53-1P 654021-59-7P
654021-66-6P 654021-72-4P 654021-77-9P
654021-83-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(target compound; preparation of diarylcyclic ureas as MCH receptor
modulators

for the treatment of obesity)


RN 654010-68-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-
phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 654010-79-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[3-amino-4-[[2-(dimethylamino)ethyl]amino]phenyl]-1,3-
dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



Updated Search

10501317


RN 654010-85-2 HCAPLUS

CN Formic acid, compd. with 1,3-dihydro-1-(4-phenoxyphenyl)-3-[3-(phenylmethyl)-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2H-imidazol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 654010-84-1

CMF C34 H33 N3 O3



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 654010-92-1 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(2-phenylethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 654010-99-8 HCAPLUS


CN Formic acid, compd. with 1,3-dihydro-1-[4-[2-(methylamino)ethoxy]phenyl]-3-(4-phenoxyphenyl)-2H-imidazol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

Updated Search


10501317

CRN 654010-98-7
CMF C24 H23 N3 O3



CM 2

CRN 64-18-6
CMF C H2 O2




RN 654011-07-1 HCAPLUS
CN Formic acid, compd. with 1-[4-(2-aminoethoxy)phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)-2H-imidazol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 654011-06-0
CMF C23 H21 N3 O3


Updated Search

10501317



CM 2

CRN 64-18-6
CMF C H2 O2




RN 654011-15-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[3-(dimethylamino)propoxy]phenyl]-1,3-dihydro-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 654011-14-0
CMF C25 H31 N3 O3


Updated Search

10501317



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 654011-29-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]-1,3-dihydro-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 654011-28-6
CMF C25 H32 N4 O2


Updated Search

10501317



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 654011-41-3 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search


10501317



RN 654011-47-9 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(1R,5S)-1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 654011-54-8 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(4-thiomorpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A




RN 654011-60-6 HCAPLUS
CN 3-Piperidinecarboxamide, 1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

Updated Search




RN 654011-65-1 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654011-71-9 HCAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl[2-(2-pyridinyl)ethyl]amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654011-76-4 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(4-phenylbutyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Updated Search

10501317


Ph-(CH₂)₄-NH-CH₂-CH₂-O




RN 654011-82-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(cyclopentyl-2-propenylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 654011-88-8 HCAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2-phenoxyethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654011-93-5 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-[[2-(1-cyclohexen-1-yl)ethyl]amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317



PAGE 1-A



PAGE 2-A




RN 654011-99-1 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[[[(1-hydroxycyclohexyl)methyl]amino]
ethoxy]phenyl]-3-(4-phenoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 654012-05-2 HCAPLUS
 CN 2H-Azepin-2-one, 3-[[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]amino]hexahydro-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10501317




RN 654012-10-9 HCAPLUS

CN Piperazine, 1-acetyl-4-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 654012-16-5 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654012-21-2 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(5-hydroxypentyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654012-27-8 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[[[(tetrahydro-2-furanyl)methyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



Updated Search


10501317

PAGE 2-A




RN 654012-33-6 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(4-hydroxy-1-piperidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654012-37-0 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654012-43-8 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(4-methyl-1-piperidinyloxy)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654012-48-3 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-[(diphenylmethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654012-58-5 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(phenylmethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654012-63-2 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(2-thienylmethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A




RN 654012-69-8 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[4-(phenylmethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654012-75-6 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(3-thiazolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 654012-80-3 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(2-phenylethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search


10501317



RN 654012-86-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(cyclopropylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



Updated Search


10501317

PAGE 2-A




RN 654012-92-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(cyclohexylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654012-97-2 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654013-02-2 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[[2-(4-pyridinyl)ethyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



Updated Search



RN 654013-06-6 HCAPLUS


CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]
]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

RN 654013-10-2 HCAPLUS


CN Acetamide, N-[1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654013-15-7 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(4-hydroxy-4-phenyl-1-piperidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654013-18-0 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-{2-(1H-imidazol-1-yl)ethoxy}phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654013-21-5 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(1H-pyrazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654013-26-0 HCAPLUS

CN L-Proline, 1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search

10501317



RN 654013-30-6 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-[(2,3-dihydro-1H-inden-2-yl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654013-35-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(2-ethyl-1-piperidinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A




RN 654013-41-9 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-[(cyclopropylmethyl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search




RN 654013-47-5 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-[(2,3-dihydro-1H-inden-1-yl)amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654013-51-1 HCAPLUS
 CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317




RN 654013-57-7 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[4-(2-phenylethyl)-1-piperazinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 654013-60-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(1H-benzimidazol-1-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654013-63-5 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-[[2-(3-methoxyphenyl)ethyl]amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A





PAGE 2-A




RN 654013-67-9 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search




RN 654013-72-6 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(4-ethyl-1-piperazinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654013-76-0 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI), (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A




RN 654013-80-6 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654013-84-0 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[[[(1R,2S)-2-phenylcyclopropyl]amino]ethoxy]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Updated Search


10501317



RN 654013-87-3 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 654013-91-9 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 654013-94-2 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[[2-(1H-indol-3-yl)ethyl]methylamino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search


10501317




RN 654013-97-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[[2-(2-chlorophenyl)ethyl]amino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




Updated Search

10501317


RN 654014-00-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[[5-chloro-2-thienyl)methyl]amino]ethoxy]phenyl
1]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 654014-02-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[[4-[[2-[[[(1R,2R)-2-(phenylmethoxy)cyclopentyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 654014-05-8 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[[[(2S)-1,2,3,4-tetrahydro-8-methoxy-2-naphthalenyl]amino]ethoxy]phenyl]]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




RN 654014-09-2 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



Updated Search



RN 654014-11-6 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(5-bromo-2,3-dihydro-1H-indol-1-yl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 654014-13-8 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(5-ethyl-2-methyl-1-piperidinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654014-15-0 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A



RN 654014-19-4 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(methylpropylamino)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654014-24-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-[(1,3-dioxolan-2-ylmethyl)methylamino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




10501317

PAGE 2-A




RN 654014-29-6 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-(2-methyl-1-pyrrolidinyl)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654014-34-3 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(1-methylethyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search

10501317




```

RN      654014-38-7  HCAPLUS
CN      2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2R)-2-(methoxymethyl)-1-
pyrrolidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI)  (CA INDEX NAME)

```

Absolute stereochemistry.




RN 654014-43-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[2-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenoxy]ethyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10501317



RN 654014-49-0 HCAPLUS

CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]
phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654014-53-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(7-azabicyclo[2.2.1]hept-7-yl)ethoxy]phenyl]-
1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654014-59-2 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(1-(phenylmethyl)-3-pyrrolidinyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 654014-64-9 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[methyl(tetrahydro-1,1-dioxido-3-

Updated Search


10501317

thienyl)amino]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 654014-68-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[(diphenylmethyl)methylamino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654014-73-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-[[[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]methylamino]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10501317



RN 654014-78-5 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-[3-(dimethylamino)-1-pyrrolidinyl]ethoxy]phenyl]-1,3-dihydro-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)


PAGE 1-A



Updated Search


10501317

PAGE 2-A




RN 654014-82-1 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(2-phenyl-1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 654014-88-7 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[2-(phenylmethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A




RN 654014-93-4 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[2-(2-phenylethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654014-97-8 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[2-(1-methylethyl)-1-pyrrolidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)-. (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654015-02-8 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-(3-phenyl-1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A



RN 654015-08-4 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-(4-phenoxyphenyl)-3-[4-[2-[(3-phenylmethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search




RN 654015-13-1 HCAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-1-[4-[2-[3-(methysulfonyl)-1-pyrrolidinyl]ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A



RN 654015-19-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654015-24-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-phenylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 654015-32-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-methylbutoxy)phenyl]- (9CI) (CA INDEX NAME)

Updated Search


10501317



RN 654015-37-9 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[(2-methylphenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




10501317

PAGE 2-A




RN 654015-42-6 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-
[(3-methylphenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 654015-47-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-
[(4-methylphenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)

Updated Search




RN 654015-51-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(2,2-dimethylpropoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10501317



RN 654015-57-3 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 654015-62-0 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(2-ethylbutoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10501317



RN 654015-66-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-(4-ethoxyphenyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 654015-71-1 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)

10501317



RN 654015-76-6 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-propynyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 654015-81-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)


10501317



RN 654015-86-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[(2E)-2-butenyloxy]phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 654015-91-5 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(4-propoxyphenyl)- (9CI) (CA INDEX NAME)

Updated Search

10501317




RN 654015-96-0 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(3-butenyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654016-02-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-(4-butoxyphenyl)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Updated Search

10501317




RN 654016-07-6 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(hexyloxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 654016-10-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopropylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654016-15-6 HCAPLUS



CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 654016-21-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclohexylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Updated Search




RN 654016-25-8 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-{2-(dimethylamino)ethoxy}phenyl]-3-[4-(1,3-dioxolan-2-ylmethoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10501317



RN 654016-29-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclohexyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654016-34-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cycloheptyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search


10501317




RN 654016-39-4 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 654016-45-2 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-
 [(4-methylcyclohexyl)oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654016-49-6 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-
 [(tetrahydro-2-furanyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317



RN 654016-53-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(1-ethylbutoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654016-58-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(4-fluorobutoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654016-63-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclobutylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654016-68-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(3,3-dimethylbutoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654016-73-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4,4,4-trifluorobutoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 654016-79-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(bicyclo[2.2.1]hept-5-en-2-ylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654016-82-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[(2-methyl-2-propenyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Updated Search


10501317



RN 654016-86-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-yloxy]phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 654016-90-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-butynyloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654016-94-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4,4,4-trifluoro-2-methylbutoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 654017-02-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-nitrophenoxy)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-07-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 654017-11-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(2-chlorophenoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-15-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 654017-20-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(3-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-25-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(3-chlorophenoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654017-30-8 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(3-methoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-35-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 654017-40-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[1,1'-biphenyl]-4-yl-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-45-5 HCAPLUS


CN 2H-Imidazol-2-one, 1-(4-butylphenyl)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 654017-50-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[2-methoxy-4-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)

10501317



RN 654017-55-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 654017-60-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(phenylmethyl)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654017-64-8 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4-pyridinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




10501317

PAGE 2-A



RN 654017-68-2 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(4-methylphenoxy)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654017-73-9 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(phenylthio)phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-78-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-[3-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654017-83-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-(4-butyl-2-methylphenyl)-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-87-5 HCAPLUS

CN [1,1'-Biphenyl]-4-carbonitrile, 4'-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 654017-92-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[3-chloro-4-(2-pyrimidinylloxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654017-97-7 HCAPLUS


CN 3-Furancarboxylic acid, 5-[4-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenyl]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 654018-02-7 HCAPLUS


CN Piperidine, 1-[4-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]benzoyl]- (9CI) (CA INDEX NAME)

10501317



RN 654018-07-2 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-
[(heptafluoropropyl)thio]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 654018-12-9 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(4-
fluorophenoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Updated Search




|
F

RN 654018-17-4 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-pyrimidinyl)oxy]phenyl- (9CI) (CA INDEX NAME)




RN 654018-21-0 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(2-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

10501317



RN 654018-26-5 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-(6-methoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 654018-31-2 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(1,3-dithiolan-2-yl)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654018-36-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(2-thienylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 654018-41-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[3-chloro-4-(1-piperidinyl)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654018-46-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-[4-(2-fluorophenoxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654018-51-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317





RN 654018-56-1 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-1,3-dihydro-3-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 654018-67-4 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[[2-(1H-imidazol-1-yl)ethyl]methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 654018-72-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[methyl[2-(2-methyl-1H-imidazol-1-yl)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10501317



PAGE 1-A





PAGE 2-A



RN 654018-83-4 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[methyl[2-(1-piperidiny)ethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 654018-90-3 HCAPLUS
 CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[[2-
 [(cyclopropylmethyl)amino]ethyl]methylamino]phenyl]-1,3-dihydro- (9CI)
 (CA INDEX NAME)




RN 654018-96-9 HCAPLUS
CN Acetamide, N-[2-[[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenyl]methylamino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

10501317



RN 654019-01-9 HCAPLUS

CN 2-Imidazolidinone, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-3-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 654019-07-5 HCAPLUS

CN 2-Imidazolidinone, 1-[4-(cyclopropylmethoxy)phenyl]-3-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317



RN 654019-28-0 HCAPLUS

CN Acetamide, N-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 654019-35-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4H-1,2,4-triazol-4-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654019-41-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-
[(cyclopropylmethyl)methylamino]ethoxy]phenyl]-1,3-dihydro- (9CI) (CA
INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 654019-47-3 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search


10501317



RN 654019-52-0 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[[[1-(hydroxycyclohexyl)methyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A







RN 654019-57-5 HCAPLUS

CN Piperazine, 1-acetyl-4-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)





RN 654019-63-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-hydroxy-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654019-69-9 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-methyl-1-piperidinyloxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654019-73-5 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(cyclopropylamino)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654019-79-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(cyclohexylamino)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A



RN 654019-84-8 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)


10501317

i-PrNH-CH₂-CH₂-O



RN 654019-89-3 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4-ethyl-1-piperazinyl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 654019-94-0 HCAPLUS


CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A



RN 654019-99-5 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[methyl(1-methylethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Updated Search


10501317



RN 654020-05-0 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 654020-10-7 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-[2-(7-azabicyclo[2.2.1]hept-7-yl)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317




RN 654020-15-2 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-[(3-(dimethylamino)-1-pyrrolidinyl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




10501317


RN 654020-20-9 HCAPLUS

CN Acetamide, N-[1-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 654020-25-4 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-hydroxy-4-phenyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A





RN 654020-29-8 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Updated Search



RN 654020-35-6 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-methyl-1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654020-41-4 HCAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[4-[3-[4-(cyclopentyloxy)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]phenoxy]ethyl]-N,N-dimethyl-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

10501317



RN 654020-46-9 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654020-51-6 HCAPLUS

CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654020-56-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-methyl-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654020-60-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2-ethyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654020-66-3 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2,4-dimethyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (9CI) . (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654020-71-0 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-[2-(2-chloro-1H-imidazol-1-yl)ethoxy]phenyl]-3-[4-(cyclopentyloxy)phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A



PAGE 2-A




RN 654020-75-4 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(2-ethyl-4-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A





PAGE 2-A





RN 654020-80-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-[2-(1-methylethyl)-1H-imidazol-1-yl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)

Updated Search




RN 654020-86-7 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2,4,5-trimethyl-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 654020-92-5 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A




PAGE 2-A




RN 654020-99-2 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A





PAGE 2-A



RN 654021-04-2 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-methyl-4-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search




RN 654021-10-0 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(5-methyl-4-nitro-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A





PAGE 2-A



```
RN 654021-16-6 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4,5-dichloro-1H-
imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)
```


Updated Search




RN 654021-22-4 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(2-phenyl-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A





PAGE 2-A



RN 654021-27-9 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-1,3-dihydro-3-[4-[2-(4-phenyl-1H-imidazol-1-yl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


Updated Search




RN 654021-32-6 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

10501317

PAGE 1-A



PAGE 2-A




RN 654021-37-1 HCAPLUS
CN 2H-Imidazol-2-one, 1-[4-(cyclopentyloxy)phenyl]-3-[4-[2-(4,5-dihydro-4,4-dimethyl-1H-imidazol-1-yl)ethoxy]phenyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


Updated Search

10501317

PAGE 1-A




PAGE 2-A




RN .654021-48-4 HCAPLUS
CN Acetamide, N-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)

10501317




RN 654021-53-1 HCAPLUS
CN 1-Piperidineacetamide, N-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





Updated Search



RN 654021-59-7 HCAPLUS
CN Propanamide, N-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenyl]-3-(methylamino)- (9CI) (CA INDEX NAME)




RN 654021-66-6 HCAPLUS
CN 1H-Imidazole-1-propanamide, N-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenyl]-2-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 654021-72-4 HCAPLUS

CN 1-Imidazolidineacetamide, N-[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenyl]-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 654021-77-9 HCAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[4-[2,3-dihydro-2-oxo-3-(4-


10501317

phenoxyphenyl)-1H-imidazol-1-yl]phenyl]amino]-3-oxopropyl]-, ethyl ester
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 654021-83-7 HCAPLUS

CN Acetamide, N-[2-[[4-[2,3-dihydro-2-oxo-3-(4-phenoxyphenyl)-1H-imidazol-1-yl]phenyl]amino]-2-oxoethyl]-N-methyl- (9CI) (CA INDEX NAME)

10501317



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:837035 HCAPLUS
 DOCUMENT NUMBER: 139:337787
 TITLE: Preparation of novel methoxybenzamides for use in MCH receptor related disorders
 INVENTOR(S): Hoegberg, Thomas; Bjurling, Anna Emelie; Receveur, Jean-Marie; Little, Paul Brian; Elling, Christian E.; Norregaard, Pia Karina; Ulven, Trond
 PATENT ASSIGNEE(S): 7TM Pharma A/S, Den.
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087045	A1	20031023	WO 2003-DK231	20030408
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2482341	A1	20031023	CA 2003-2482341	20030408
AU 2003226926	A1	20031027	AU 2003-226926	20030408
EP 1497260	A1	20050119	EP 2003-746255	20030408
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2006235035	A1	20061019	US 2005-510907	20050516

Updated Search



10501317

PRIORITY APPLN. INFO.:

DK 2002-519	A 20020409
DK 2002-520	A 20020409
DK 2002-524	A 20020409
DK 2002-1818	A 20021125
WO 2003-DK231	W 20030408

OTHER SOURCE(S):
GI

MARPAT 139:337787



II

AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7, SO2NR7, CHR7NR7CO, NR7COR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, CH=CH, OCHR7, NR7CHR7, SCHR7, or (un)substituted imidazolediyl or 1,2,4-triazolediyl; Ar = independently (hetero)aryl; R1 = alkoxy; R2 = H, OH, NH2, or alkoxy; COQ = amino-substituted amide; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl, carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; R7 = independently H, alkyl, or alkenyl; R8 = halo, (alkyl)(cyclo)alkyl, alkenyl, alkynyl, (alkyl)(hetero)aryl, (alkyl)heterocyclyl, (aryl)alkoxy, aryloxy, dialkylamino, (di)alkylcarbamoyle, (di)arylcarbamoyle, alkanoyl(amino), aroyl(amino), SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, or R6ArB; B = a single bond or connecting moiety; X = H, halo, SMe, CF3, OCF3, SCF3, OMe, alkyl, or alkenyl; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepared as

melanin-concentrating

hormone (MCH) receptor modulators. For example, coupling of procainamide with 4-trifluoromethoxyphenyl isocyanate in the presence of TEA in CH2Cl2 gave II (59%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.07 μ M and 0.29 μ M, resp. Administration of II (10 mg/kg i.p.) to male Sprague Dawley rats resulted in a significant reduction of their cumulative food intake over 6 h. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression, diabetes, bulimia, and other MCH receptor related disorders (no data).

IT 617246-13-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


Updated Search

10501317

(MCH receptor modulator; preparation of methoxybenzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617246-13-6 HCAPLUS

CN Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-4-[2-oxo-3-(4-phenoxyphenyl)-1-imidazolidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 14 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:485719 HCAPLUS

DOCUMENT NUMBER: 139:53315

TITLE: Preparation of N-sulfonylated dipeptide derivatives as inhibitors of leukocyte adhesion mediated by VLA-4
INVENTOR(S): Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Kreft, Anthony; Konradi, Andrei W.; Grant, Francine S.; Baudy, Reinhardt Bernhard; Sarantakis, Dimitrios

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 81 pp., Cont.-in-part of U.S. Ser. No. 127,346, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6583139	B1	20030624	US 2000-688820	20001017
US 2004006093	A1	20040108	US 2003-382988	20030307
PRIORITY APPLN. INFO.:			US 1997-104592P	P 19970731
			US 1998-127346	B1 19980731
			US 2000-688820	A1 20001017

OTHER SOURCE(S): MARPAT 139:53315

AB Disclosed are N-sulfonylated dipeptides R1SO2NR2CHR3-Q-CHR5CO2H [R1, R3 =

Updated Search

(un)substituted alkyl, aryl, cycloalkyl, heterocyclyl or heteroaryl; R2 = H, (un)substituted cycloalkenyl, or any group given for R1; or R2 may form an (un)substituted heterocyclic ring with R1 or R3; R5 = CH2-X', where X' = H, OH, acylamino, (cyclo)alkyl, alkoxy, aryloxy, (hetero)aryl, aryloxyalkyl, carboxy, carboxyalkyl, etc.; Q = C(X)NR7; R7 = H, alkyl; X = O, S (with provisos)] which bind VLA-4. Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, coupling of N-tosyl-L-proline with L-tyrosine Me ester, followed by reaction with (1-bromoethyl)benzene and saponification, afforded N-tosyl-L-prolyl-4-(α -methylbenzyloxy)-L-phenylalanine.

IT 220303-56-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-sulfonylated dipeptide derivs. as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220303-56-0 HCAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:504766 HCAPLUS

DOCUMENT NUMBER: 137:78944

TITLE: Preparation of aryloxazolones as antibacterials.

INVENTOR(S): Natesan, Selvakumar; Das, Jagattaran; Iqbal, Javed; Magadi, Sitaram Kumar; Mamidi, Naga Venkata Srinivasa Rao; Ramanujam, Rajagopalan; Sundarababu, Baskaran; Lohray, Braj Bhushan

PATENT ASSIGNEE(S): Dr. Reddy's Research Foundation, India; Dr. Reddy's Laboratories Ltd.

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



10501317

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051819	A2	20020704	WO 2001-IN227	20011226
WO 2002051819	A3	20021205		
WO 2002051819	A9	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2000MA01124	A	20050304	IN 2000-MA1124	20001226
CA 2433138	A1	20020704	CA 2001-2433138	20011226
AU 2002226669	A1	20020708	AU 2002-226669	20011226
EP 1345913	A2	20030924	EP 2001-995805	20011226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200302580	A2	20031128	HU 2003-2580	20011226
EE 200300254	A	20031215	EE 2003-254	20011226
BR 2001016571	A	20040302	BR 2001-16571	20011226
JP 2004525876	T	20040826	JP 2002-552914	20011226
CN 1656083	A	20050817	CN 2001-822421	20011226
NZ 526716	A	20050826	NZ 2001-526716	20011226
NO 2003002926	A	20030825	NO 2003-2926	20030625
MX 2003PA05822	A	20040504	MX 2003-PA5822	20030625
ZA 2003004945	A	20040927	ZA 2003-4945	20030625
BG 108022	A	20040930	BG 2003-108022	20030722
PRIORITY APPLN. INFO.:				
			IN 2000-MA1124	A 20001226
			IN 2001-MA15	A 20010104
			WO 2001-IN227	W 20011226

OTHER SOURCE(S): MARPAT 137:78944

GI



Updated Search

10501317

AB Title compds. [I; R1 = halo, N3, SCN, SH, OR4, NHR4, N(R4)2; R4 = H, (substituted) acyl, thioacyl, alkoxycarbonyl, cycloalkoxythiocarbonyl, alkenyloxycarbonyl, alkenylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, alkenyloxythiocarbonyl, aryloxythiocarbonyl, COCOA, COCOAr, COCOAlk, COCOArO, CS2A, CSNH2, CSNHA, CSNA2, CSNHAK, CSCOAlk, CSCOArO, CSO2CA, CSCSA, CSCSAr, thiomorpholinylthiocarbonyl, pyrrolidinylthiocarbonyl; A = alkyl; Ar = aryl; Alk = alkoxy; Ak = alkenyl; R2, R3 = H, halo, alkyl, haloalkyl, cyano, nitro, SRa, NRA, ORa; Ra = (substituted) alkyl, haloalkyl; Z = S, O, CH, NRb; Rb = H, (substituted) alkyl, alkenyl, cycloalkyl, alkoxy, aryl, aralkyl, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl; Y1 = O, S; Y2, Y3 = H, halo, cyano, NO2, formyl, OH, amino, O, S, (substituted) alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino, alkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl heterocycloalkyl; adjacent Y2Y3 form a (substituted) 5-6 membered aromatic or nonarom. cyclic structure, optionally containing 1-2 heteroatoms], were prepared Thus, title compound (II) (general preparation given) showed a min. inhibitory concentration of 0.25 µg/mL

against

Staphylococcus aureus 019 MRSA.

IT 439902-74-6P 439902-75-7P 439902-86-0P
439902-87-1P 439903-25-0P 439903-26-1P
439903-36-3P 439903-76-1P 439903-77-2P
439903-78-3P 439903-79-4P 439903-80-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloxazolones as antibacterials)

RN 439902-74-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439902-75-7 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 439902-86-0 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439902-87-1 HCAPLUS

CN 2-Oxazolidinone, 5-(azidomethyl)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 439903-25-0 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439903-26-1 HCAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

CC(=O)NCC1SCC(=O)N1C2=CC=C(N3C(=O)N(C4=CC=C(F)C4)CC3)C=C(F)C2


RN	459989-36-9	NON-100
CN	Ethanethioamide, N-[[[(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl)methyl]-(9CI)	(CA INDEX NAME)

CN(C(=S)C)N[C@@H]1C(=O)N(c2ccc(N3C(=O)N(C3)c4ccccc4)c(F)c4ccccc24)C1

Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI)
(CA INDEX NAME)

Updated Search


10501317



RN 439903-77-2 HCAPLUS

CN Carbamothioic acid, [[[5S)-3-[3-fluoro-4-(2-oxo-3-phenyl-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 439903-78-3 HCAPLUS

CN Carbamothioic acid, [[[5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10501317



RN 439903-79-4 HCAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 439903-80-7 HCAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-[3-(4-fluorophenyl)-2-oxo-1-imidazolidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)

Updated Search

10501317

Absolute stereochemistry.



L18 ANSWER 16 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:242231 HCAPLUS

DOCUMENT NUMBER: 137:124951

TITLE: Novel 1,4-diphosphanes with imidazolidin-2-one
backbones as chiral ligands: highly enantioselective
Rh-catalyzed hydrogenation of enamides

AUTHOR(S): Lee, Sang-Gi; Zhang, Yong Jian; Song, Choong Eui; Lee,
Jae Kyun; Choi, Jung Hoon

CORPORATE SOURCE: Life Sciences Division, Korea Institute of Science and
Technology, Seoul, 130-650, S. Korea

SOURCE: Angewandte Chemie, International Edition (2002),
41(5), 847-849

CODEN: ACIEF5; ISSN: 1433-7851


PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:124951

GI



AB Asym. hydrogenation of N-acetyl α -aryl enamides ArC(:CHR1)NHAc [Ar =

Updated Search

10501317

(un)substituted Ph; R1 = H, Me, Et] was catalyzed by [Rh(cod)2]BF4 and 1,4-diphosphane ligands I (R = H, Me, Et, etc.). I were prepared from a L-tartaric acid derivative

IT 444024-90-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(asym. hydrogenation of N-acetyl α -aryl enamides catalyzed by [Rh(cod)2]BF4 and 1,4-diphosphane ligands)

RN 444024-90-2 HCAPLUS

CN 2-Imidazolidinone, 1,3-diphenyl-4,5-bis[(phenylmethoxy)methyl]-, (4S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 17 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:152312 HCAPLUS

DOCUMENT NUMBER: 130:196959

TITLE: Solid-phase synthesis of N-substituted glycine peptide combinatorial libraries and nitrogen heterocycle combinatorial libraries

INVENTOR(S): Zuckermann, Ronald N.; Goff, Dane A.; Ng, Simon; Spear, Kerry; Scott, Barbara O.; Sigmund, Aaron C.; Goldsmith, Richard A.; Marlowe, Charles K.; Pei, Yazhong; Richter, Lutz; Simon, Reyna

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: U.S., 50 pp., Cont.-in-part of U.S. Ser. No. 277,228, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5877278	A	19990302	US 1995-487282	19950607
EP 1258492	A1	20021120	EP 2002-77404	19930924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5831005	A	19981103	US 1995-441826	19950516
US 5977301	A	19991102	US 1995-485106	19950607
CA 2221517	A1	19961219	CA 1996-2221517	19960604
WO 9640202	A1	19961219	WO 1996-US8832	19960604
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				

Updated Search

10501317

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML
 AU 9662534 A 19961230 AU 1996-62534 19960604
 EP 789577 A1 19970820 EP 1996-921278 19960604
 EP 789577 B1 20030312

R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

JP 11507049 T 19990622 JP 1996-501317 19960604
 JP 11507049 T 19990622 JP 1997-501317 19960604
 JP 3943593 B2 20070711
 AT 234268 T 20030315 AT 1996-921278 19960604
 JP 2000239242 A 20000905 JP 2000-38885 20000216
 JP 3596752 B2 20041202
 US 2002115612 A1 20020822 US 2002-71577 20020208
 JP 2006182780 A 20060713 JP 2005-365635 20051219

PRIORITY APPLN. INFO.:

US 1992-950853 B2 19920924
 US 1993-126539 B2 19930924
 US 1994-277228 B2 19940718
 EP 1993-923131 A3 19930924
 JP 1994-508459 A3 19930924
 US 1995-454511 B3 19950530
 US 1995-487282 A 19950607
 JP 1997-501317 A3 19960604
 WO 1996-US8832 W 19960604
 US 2000-573700 B3 20000519

AB A solid-phase method for the synthesis of N-substituted oligomers, such as poly(N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs can have a wide variety of side chain substituents. Each N-substituted glycine monomer is assembled from two "sub-monomers" directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by NH₂, such as a haloacetic acid, and (2) introduction of the side chain by nucleophilic displacement of the leaving group, such as halogen (as a solid support-bound α -haloacetamide) with a sufficient amount of a second sub-monomer comprising an NH₂ group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate, or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using automated synthesis technol. of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compds. not found in nature, but which are synthetically accessible and have been shown to possess significant biol. activity and proteolytic stability. Combinatorial libraries of cyclic compds. are disclosed wherein the cyclic compds. are comprised of at least one ring structure derived from cyclization of a peptoid backbone. The diversity of product compds. is generated by the sequential addition of substituted submonomers. The combinatorial library includes 10 or more, preferably 100 or more, and more preferably 1,000 or more distinct and different compds. The library includes each of the product compds. in retrievable and analyzable amts. and preferably includes at least one biol. active compound. Methods of synthesizing the combinatorial libraries and assay devices produced using the libraries are disclosed, as is methodol. for screening for and obtaining biol. active cyclic organic compds.

IT 220826-86-8P 220826-90-4P


Updated Search

10501317

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase preparation of N-substituted glycine peptide combinatorial libraries and nitrogen heterocycle combinatorial libraries)


RN 220826-86-8 HCAPLUS

CN 4-Imidazolidineacetamide, N-(2-amino-2-oxoethyl)-N-(2-methylpropyl)-2-oxo-1,3-diphenyl- (9CI) (CA INDEX NAME)



RN 220826-90-4 HCAPLUS

CN 4-Imidazolidineacetamide, N-(2-amino-2-oxoethyl)-1-[1,1'-biphenyl]-4-yl-N-(2-methylpropyl)-2-oxo-3-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 18 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:113712 HCAPLUS

DOCUMENT NUMBER: 130:168662

TITLE: Preparation of N-sulfonylproline dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

INVENTOR(S): Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Kreft, Anthony; Konradi, Andrei W.; Grant, Francine S.; Baudy, Reinhardt Bernhard; Sarantakis, Dimitrios

PATENT ASSIGNEE(S): Athena Neurosciences, Inc., USA; American Home Products Corporation

SOURCE: PCT Int. Appl., 294 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

Updated Search

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906437	A1	19990211	WO 1998-US16070	19980731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2290748	A1	19990211	CA 1998-2290748	19980731
AU 9888234	A	19990222	AU 1998-88234	19980731
EP 994896	A1	20000426	EP 1998-939871	19980731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9811594	A	20000905	BR 1998-11594	19980731
HU 200003921	A2	20010228	HU 2000-3921	19980731
JP 2001512139	T	20010821	JP 2000-505192	19980731
MX 200000678	A	20010710	MX 2000-678	20000119
NO 2000000452	A	20000327	NO 2000-452	20000128
PRIORITY APPLN. INFO.:			US 1997-904423	A2 19970731
			WO 1998-US16070	W 19980731

OTHER SOURCE(S): MARPAT 130:168662

AB Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted heterocyclic ring; R5 = CH2X1; X1 = H, OH, acylamino, (un)substituted alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, CO2H, carboxyalkyl, carboxyaryl, carboxyheteroaryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyloxy, adamantylamino, β -cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z'; R11 = alkyl; Z' = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind VLA-4 (also referred to as integrin $\alpha 4\beta 1$ and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, BOP-mediated peptide coupling of Ts-Pro-OH (Ts = tosyl) with H-Tyr-OMe gave 75% of the corresponding ester, which underwent saponification

in quant. yield to give desired dipeptide Ts-Pro-Tyr-OH. All prepared compds. have $IC_{50} \leq 15 \mu M$ in a VLA-4 binding assay.

IT 220303-56-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-sulfonylproline dipeptide derivs. and analogs as


10501317

inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220303-56-0 HCAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-(3-chlorophenyl)-2,4,5-trioxo-1-imidazolidinyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 19 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:13992 HCAPLUS

DOCUMENT NUMBER: 130:66504

TITLE: Preparation of cyclic ureas for the treatment of thrombosis

INVENTOR(S): Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhard; Linz, Guenter; Weisenberger, Johannes; Eisert, Wolfgang; Mueller, Thomas

PATENT ASSIGNEE(S): Karl Thomae GmbH, Germany

SOURCE: U.S., 43 pp.; Cont.-in-part of U.S. 5.650.424.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5852192	A	19981222	US 1997-847048	19970501
US 5276049	A	19940104	US 1992-849557	19920311
US 5478942	A	19951226	US 1993-144909	19931028
US 5650424	A	19970722	US 1995-521338	19950829
PRIORITY APPLN. INFO.:			US 1992-849557	A3 19920311
			US 1993-144909	A3 19931028
			US 1995-521338	A2 19950829
			DE 1991-4107857	A 19910312

OTHER SOURCE(S): MARPAT 130:66504
GI

Updated Search




AB The title compds. [I; X = O; Y = ethylene; one of R1 or R2 = ABC (wherein A = C1-5 aminoalkyl, amino, amidino, etc.; b = a bond; C = (un)substituted phenylene); the other of R1 or R2 = FED (D = (un)substituted cyclohexaline, etc.; E = (un)substituted C1-5 alkylene, C2-5 alkenylene; F = carbonyl substituted by a hydroxy or C1-6 alkoxy, etc.)], useful for the treatment of thrombosis, were prepared and formulated. Thus, treatment of 1-(4'-amidino-4-biphenyl)-3-methoxycarbonylmethyl-imidazolidin-2-one.HCl in MeOH with 1N NaOH afforded II which showed IC50 of 1,800 nM against fibrinogen binding and EC50 of 9,900 nM for platelet aggregation inhibition.

IT 144655-46-9P 218162-62-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic ureas for the treatment of thrombosis)


RN 144655-46-9 HCAPLUS

CN Phenylalanine, 4-[3-(4-cyanophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-N,N-bis(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 218162-62-0 HCAPLUS

CN Phenylalanine, 4-[3-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 20 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN.

ACCESSION NUMBER: 1998:159561 HCAPLUS

DOCUMENT NUMBER: 128:217324

TITLE: The synthesis of 2-imidazolidones on solid support by tandem aminoacylation/Michael addition

AUTHOR(S): Goff, Dane

CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA

SOURCE: Tetrahedron Letters (1998), 39(12), 1477-1480

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Reaction of isocyanates with unsatd. amines bound to a solid support can lead either to 2-imidazolidones or 2-iminooxazolidinones depending on conditions. The imidazolidones are a useful new framework for combinatorial library synthesis.


IT 204330-02-9P 204330-09-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of imidazolidones on solid support by tandem aminoacylation/Michael addition)

RN 204330-02-9 HCAPLUS


CN 4-Imidazolidineacetamide, N-(2-amino-2-oxoethyl)-3-(2-bromophenyl)-N-(2-methylpropyl)-2-oxo-1-phenyl- (9CI) (CA INDEX NAME)

10501317



RN 204330-09-6 HCAPLUS

CN 4-Imidazolidineacetamide, N-(2-amino-2-oxoethyl)-1-[1,1'-biphenyl]-4-yl-3-(2-bromophenyl)-N-(2-methylpropyl)-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 21 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:101980 HCAPLUS

DOCUMENT NUMBER: 118:101980

TITLE: Preparation of cyclic ureas as cell-cell and cell-matrix interaction inhibitors

INVENTOR(S): Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhard; Linz, Guenter; Mueller, Thomas; Weisenberger, Johannes; Eisert, Wolfgang

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany

SOURCE: Eur. Pat. Appl., 91 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 503548	A1	19920916	EP 1992-104045	19920310

Updated Search

10501317

EP 503548	B1	19970604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
DE 4107857	A1	19920917	DE 1991-4107857	19910312
FI 9201030	A	19920913	FI 1992-1030	19920310
AT 154013	T	19970615	AT 1992-104045	19920310
ES 2104754	T3	19971016	ES 1992-104045	19920310
CA 2062655	A1	19920913	CA 1992-2062655	19920311
NO 9200957	A	19920914	NO 1992-957	19920311
AU 9212803	A	19920917	AU 1992-12803	19920311
AU 654340	B2	19941103		
HU 60722	A2	19921028	HU 1992-823	19920311
ZA 9201804	A	19930913	ZA 1992-1804	19920311
IL 101203	A	19951231	IL 1992-101203	19920311
JP 04368372	A	19921221	JP 1992-53171	19920312
PRIORITY APPLN. INFO.:			DE 1991-4107857	A 19910312
OTHER SOURCE(S):			CASREACT 118:101980; MARPAT 118:101980	
GI				



I

AB Title compds. [I; X = CO, CS, SO, SO₂, (substituted) carbimino; Y = (R₂, R₃-substituted) C₂-4 alkylene, alkenylene, C₄-7 cycloalkenylene, CONH, CH:N, etc.; one of R-R₃ = A-B-C; A = (substituted) aminoalkyl, amino, amidino, guanidino, cyano, cyanoalkyl; B = bond, alkylene, alkenylene, (substituted) phenylene, pyridinylene, pyrimidinylene, pyrazinylene, cyclopropylene, biphenylene, etc.; C = (substituted) alkylene, alkenylene, alkylencarbonyl, phenylene, indanylene, tetrahydronaphthalenediyl, pyridinylene, pyrimidinylene, pyrazinylene, pyridazinylene, triazinylene, cycloalkylene, etc.; another of R-R₃ = F-E-D; D = alkylene, alkenylene, (substituted) phenylene, pyridinylene, pyrimidinylene, pyrazinylene, pyridazinylene, triazinylene, cycloalkylene, etc.; E = bond, (substituted) alkylene, phenylene, pyridinylene, pyrimidinylene, pyrazinylene, pyridazinylene, triazinylene, cycloalkylene, etc.; F = CO₂H, (substituted) alkoxycarbonyl; the third of R-R₃ = H, alkyl, perfluoroalkyl, aralkyl, (hetero)aryl, etc.; the fourth of R-R₃ = H, alkyl, aralkyl, aryl, heteroaryl; RR₂, RR₃, R1R₂, R1R₃ = bond], were prepared Thus, 1-(4'-amidino-4-biphenyl)-3-methoxycarbonylmethylimidazolidin-2-one hydrochloride was stirred with 1N NaOH in MeOH to give 1-(4'-amidino-4-biphenyl)-3-carboxymethylimidazolidin-2-one. I inhibited collagen-induced blood platelet aggregation with IC₅₀ = 30 - >100,000 nM. Generic drug formulations are given.

IT 144654-93-3P 144655-46-9P 145341-37-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as cell-cell and cell-matrix interaction inhibitor)


RN 144654-93-3 HCAPLUS

CN L-Phenylalanine, 4-[3-[4-(aminoiminomethyl)phenyl]-2-oxo-1-imidazolidinyl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search

10501317




RN 144655-46-9 HCAPLUS
CN Phenylalanine, 4-[3-(4-cyanophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-
N,N-bis(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 145341-37-3 HCAPLUS
CN Phenylalanine, 4-[3-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-2-oxo-1H-
imidazol-1-yl]-N,N-bis(phenylmethyl)-, methyl ester, monohydrochloride
(9CI) (CA INDEX NAME)

Updated Search

10501317



L18 ANSWER 22 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:232431 HCAPLUS
DOCUMENT NUMBER: 112:232431
TITLE: Synthesis and antimicrobial activity of some new
2,5-imidazolidinediones
AUTHOR(S): Mohamed, A. M.; El-Sharief, A. M. S.; Ammar, Y. A.;
Aly, M. M.
CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ., Nasr City, Egypt
SOURCE: Pharmazie (1989), 44(11), 765-7
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB 1,3-Diphenyl-4-thione-2,5-imidazolidinedione (I) was reacted with amino
compds. and o-diamines to give 1,3-diphenyl-4-substituted
imino-2,5-imidazolidinediones and 1,3-diphenyl-1H-imidazo[4,5-b]quinoxaline-
2(3H)-ones, resp. Condensation of I with hydrazines afforded the
corresponding hydrazone derivs. Six of these compds. had somewhat
promising antimicrobial activity. Incorporation of the sulfonamido moiety
with the imidazolidine nucleus generated inhibitory activity.
IT 125911-79-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

Updated Search


- 10501317

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antimicrobial activity of)

RN 125911-79-7 HCAPLUS

CN 2,4-Imidazolidinedione, 1,3-diphenyl-5-[(phenylmethyl)imino]- (9CI) (CA INDEX NAME)



L18 ANSWER 23 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1982:423695 HCAPLUS

DOCUMENT NUMBER: 97:23695

TITLE: Orthoamides. XXXVII. Reactions of 2,2-bis(dialkylamino)acetonitriles and 2-(dialkylamino)-2-methoxyacetonitriles with isocyanates

AUTHOR(S): Kantlehner, Willi; Haug, Erwin; Isak, Heinz; Schulz, Wolfgang; Hippich, Silvin; Baur, Richard; Hagen, Helmut

CORPORATE SOURCE: Fachber. Chem., Fachhochsch. Aalen, Aalen, D-7080, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1982), 115(5), 1721-32


CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal


LANGUAGE: German

OTHER SOURCE(S): CASREACT 97:23695


GI



I



II



III

AB NCCH(NRR1)2 (NRR1 = NMe2, pyrrolidino, piperidino) reacted with R2NCO (R2 = Ph, 4-MeC6H4, 4-ClC6H4, Me, Bu) to give the amins I which were hydrolyzed to II (R3 = Me, Et, CH2Ph). II were also obtained by treating RR1NCH(OR3)2 with 5-imino-2,4-imidazolidinediones. 14C-labeling showed that the C-5 of the imidazolidine ring in I was derived from NCCH(NRR1)2.

Updated Search

10501317


The mechanism of the cyclization is discussed. Reaction of MeOCH(CN)NRR1 with R2NCO gave III (R4 = OMe, R5 = NRR1, R4R5 = NH).

IT 82146-47-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 82146-47-2 HCAPLUS

CN Methanimidamide, N'-[1,3-bis(3-methylphenyl)-2,5-dioxo-4-(phenylmethoxy)-4-imidazolidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



L18 ANSWER 24 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1979:103961 HCAPLUS

DOCUMENT NUMBER: 90:103961

TITLE: (Thio)hydantoin modified with amide groups

INVENTOR(S): Rottmaier, Ludwig; Merten, Rudolf

PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 19 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
DE 2722513	A1	19781130	DE 1977-2722513	19770518
US 4170701	A	19791009	US 1978-897666	19780419
JP 53132567	A	19781118	JP 1978-46004	19780420
GB 1600343	A	19811014	GB 1978-15645	19780420
FR 2387963	A1	19781117	FR 1978-11942	19780421
PRIORITY APPLN. INFO.:			DE 1977-2718103	A 19770422
			DE 1977-2722513	A 19770518

GI

Updated Search



AB Amide-substituted(thio)hydantins (optionally polymeric) were prepared by the reaction of the maleimides I [$R = R_1 = H$, aliphatic group; $R_2 = H$, (substituted) (cyclo)aliphatic, aromatic, or araliph. group; $n = 1-3$] with a primary mono- or polyamine, followed by treatment of the product with an organic mono- or polyiso(thio)cyanate, optionally in the presence of catalysts. Thus, $PhNH_2$ reacted with N-phenylmaleimide, and the product was treated with $PhNCO$ to give II.


IT 69386-01-2P 69386-02-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 69386-01-2 HCAPLUS


CN Poly[(2,5-dioxo-3-phenyl-4,1-imidazolidinediyl)-1,4-phenylenemethylene-1,4-phenylene(2,5-dioxo-3-phenyl-1,4-imidazolidinediyl)(2-oxo-1,2-ethanediyloxy)imino-1,4-phenylenemethylene-1,4-phenyleneimino(1-oxo-1,2-ethanediyloxy)] (9CI) (CA INDEX NAME)

PAGE 1-A




10501317


PAGE 2-A



RN 69386-02-3 HCAPLUS
CN Poly[[2,5-dioxo-4-[2-oxo-2-(phenylamino)ethyl]-1,3-imidazolidinediyl]-1,4-phenylenemethylene-1,4-phenylene[2,4-dioxo-5-[2-oxo-2-(phenylamino)ethyl]-1,3-imidazolidinediyl]-1,4-phenylenemethylene-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A





L18 ANSWER 25 OF 25 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1970:100629 HCAPLUS

DOCUMENT NUMBER: 72:100629

TITLE: Addition of bifunctional acyl chlorides to carbodiimides and some subsequent reactions [imidazolidines and pyrimidines]

AUTHOR(S): Zinner, Gerwalt; Vollrath, Ruediger

CORPORATE SOURCE: Inst. Pharm. Chem., Tech. Univ. Braunschweig, Brunswick, Fed. Rep. Ger.

SOURCE: Chemische Berichte (1970), 103(3), 766-76
CODEN: CHBEAM; ISSN: 0009-2940

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 72:100629

GI For diagram(s), see printed CA Issue.

AB Addition of ClCOCOC1 to 1,3-di(R-substituted)carbodiimides gave 66-79% 1,3-di(R-substituted)-2,2-dichloroimidazolidine-4,5-diones (I) (where R = Et, iso-Pr, tert-Bu, Ph, cyclohexyl, or p-MeC₆H₄). Reaction of I with dihydric alcs., mercapto alcs., dimercaptans, diamines, or pyrocatechol gave 14-90% of the spiro compds., substituted 4,5-imidazolidinediones (II) [where (R₁R₂) = O(CH₂)₂O, O(CH₂)₂S, S(CH₂)₂S, MeN(CH₂)₂NMe, o-OC₆H₄O, o-NHC₆H₄NH, O(CH₂)₃O, S(CH₂)₃S, or OCH₂CEt₂CH₂O]. Reaction of I with primary amines, hydroxylamines, or hydrazines yielded 17-91% substituted imidazolidine-4,5-diones (III) (where R = iso-Pr, cyclohexyl, or p-MeC₆H₄; and R₁ = OH, OMe, OCH₂Ph, Ph, Ph, NMe₂, piperidino, NHCO₂Et, or CN). R₁R₂C(COCl)₂ reacted similarly with carbodiimides to give substituted 2,2-di-chlorohexahydropyrimidine-4,6-diones (IV) [where R = iso-Pr or cyclohexyl; and R₁ = R₂ = Me, or (R₁R₂) = (CH₂)₃]. From IV, the spiro compds., substituted 5,5-dimethylhexahydro-pyrimidine-4,6-diones (V) [where R = iso-Pr or cyclohexyl; and (R₃R₄) = S(CH₂)₂S, NPh, or NNMe₂], were obtained. Succinyl or phthaloyl chloride reacted with 1,3-dicyclohexyl-carbodiimide to give the open chain compds., succin- or-phthalbis-(N,N'-dicyclohexylureide), resp.


IT 26263-28-5P 26263-29-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

10501317


RN 26263-28-5 HCAPLUS

CN 4,5-Imidazolidinedione, 2-hydroxy-2-[methyl[2-(methyamino)ethyl]amino]-
1,3-di-p-tolyl- (8CI) (CA INDEX NAME)



RN 26263-29-6 HCAPLUS

CN 4,5-Imidazolidinedione, 2,2'-[ethylenebis(methylimino)]bis[2-ethoxy-1,3-di-
p-tolyl- (8CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
150.09	859.00

SINCE FILE	TOTAL
ENTRY	SESSION
-21.06	-21.06

Updated Search

10501317

FILE 'CAOLD' ENTERED AT 10:57:37 ON 08 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.